INSM seems to breakout today.
Bought at 1,30.
Long term INSM may be a tenbagger.
http://bigcharts.marketwatch.com/javachart/javachart.asp?symb=insm&time=&freq= (http://bigcharts.marketwatch.com/javachart/javachart.asp?symb=insm&time=&freq=)
News:Lazard initiate INSM with $2.50 target
Initiating coverage on the two GHIS contenders
1. Growth Hormone Insensitivity (GHIS), or severe short stature, is a subset of
the $2 billion growth hormone therapy market; no approved therapies to date
2. Tercica's Increlex and Insmed's SomatoKine are both expected to receive
approval, with PDUFA dates of August 31 and October 3, 2005, respectively
3. Pediatric endocrinologists we interviewed favor Insmed's SomatoKine over
Tercica's Increlex, should both be launched concurrently, as we expect
4. INSM (current price: $1.22) is rated BUY with a $2.50 price target, as we
believe the shares are undervalued; any significant and/or lasting concern over
Increlex approval would be misplaced
5. TRCA (current price: $8.57) is rated HOLD with a $9.50 price target, as we
consider the shares to be fully valued and vulnerable to nearly any
disappointment; any regulatory delays could trigger a decline
6. Risks to INSM include potential orphan drug exclusivity for Tercica's
Increlex if approved first, while TRCA investors may be disappointed, as we
expect Increlex market acceptance to be low upon commercialization of both
products
therman
INSM begins to fly. now at 1,55.
I think this is only the beginning.
http://data.inetats.com/ds/tools/bookviewer/htmlbook.jsp?STOCK=insm
therman
:-\Kind of empty on this board...
I've got myself and at least three relatives in this stock. Waiting like everyone else. Small stake, just getting started in some real market play. Would consider myself a semi-market wise newbie, but have made some good picks in the past. Here to learn...quick!!! I think this stock has blockbuster potential, both near and long term. Did you pick up on any of the Bio conference presentation material?
Looks like approval w/orphan is expected by management and soon. Several partner candidates referenced but not by name, iPLEX is being produced at the Boulder facility and we're ready to rock. I go by the same id on the yahoo INSM board. Also following NVAX.
Check back tomorrow for signs of life...
Regards
Quote from: retvet24 on October 20, 2005, 10:59:34 PM
:-\Kind of empty on this board...
Looks like approval w/orphan is expected by management and soon. Several partner candidates referenced but not by name, iPLEX is being produced at the Boulder facility and we're ready to rock. I go by the same id on the yahoo INSM board. Also following NVAX.
Check back tomorrow for signs of life...
Not exactly tomorrow, but INSM is putting in support around $1.20 now for a week. May be a small drop to $1.15 as the wait to Dec. 12th FDA announcement drags out, but the bottom is here IMHO. The approval PR may catch people off guard, as did the "approvable" letter. I plan on getting back in post Thanksgiving-1st week Dec. with some cash extracted from NVAX.
These two stocks are about as close as I can find to "sure things"...
Regards....
Check back later for signs of life...
Regards
FDA is ok today...insm WINNER...LIVELIFE come on $$$$$
That's made$$$$$$$$$$$$$$$$$$$$$$$$$$$
There is a very good chance that the FDA will grant orphan-drug status to INSM's iPlex on 12/12/05. The company CEO seems to think so. This recent company presentation will give you some clues.
I believe that INSM will go up substantially today, Friday Dec. 9, 2005.
And there might be more news soon. From the Yahoo board:
INSM & Breast Cancer Conf. on 12/10th
by: pix_with_x
Long-Term Sentiment: Strong Buy 12/09/05 03:42 am
Msg: 35698 of 35700
Just as a reminder! INSM to present on 10th in San Antonio...And have a short look who will be present...Not the smallest ones!
http://sabcs.org/programschedule/postersessions.asp?sessiongroupid=21
Post 5081: Synergistic interaction between recombinant human insulin-like growth factor-binding protein 3 (rhIGFBP-3) and letrozole in estrogen positive breast cancer.
Alami N, Banerjee K, Page V, Brossard M, Shiry L, Brodie A, Leyland-Jones B. McGill University, Montreal, QC, Canada; Insmed Inc., Richmond, VA; University of Maryland, Baltimore, MD.
Ch, PwX
Nervous about waiting...Good or ..............bad news ...
Today, we're gonna see !
Good luck ;)
;D ;D ;D ;D ;D
FDA's approval is good.....
So....don't miss the bus..............................$$$$$$$$$$$$$
Got in AH @2.14 This one might run some more tomorrow.
Looking for 3.00 tomorrow.
>:D
AP
Insmed Shares Soar on FDA OK of Iplex
Monday December 12, 6:26 pm ET
Insmed Shares Climb 40.3 Percent After FDA OKs Iplex Therapy, Grants Treatment 'Orphan' Status
RICHMOND, Va. (AP) -- Insmed Inc. said Monday that regulators approved its Iplex therapy for children who lack a certain growth hormone and granted the treatment "orphan drug" status despite the approval of a competing drug.
As recently as October, Insmed said the Food and Drug Administration was still considering whether to make Iplex an orphan drug. The label, which carries seven years of exclusive selling rights, is designed to motivate companies to develop treatments for rare diseases.
Insmed shares surged 40.3 percent after-hours to $2.09, having closed on the Nasdaq up 2 percent at $1.49.
The drug was approved to boost the height of children with a severe deficiency of a hormone called IGF-1, or whose bodies cannot recognize growth hormones. It is delivered in a daily dose.
Insmed plans to launch the drug between April and June. Competitor Tercica Inc. received FDA approval and orphan drug exclusivity for its similar growth hormone, Increlex, in September to treat a severe deficiency of IGF-1.
Up 44% Ah................. I was going to pick this one for the contest....but....i didnt..........oh well... Tomorrow should be intersting.
Good luck to anyone holding :)
-fousc
Already a thread created: http://www.3stocksonfire.org/trading/index.php?topic=2303.msg16425#msg16425
Please do a search before posting.... >:D
Hi Calven,
FDA approval for INSM is a big news. AH volume was huge as well - just over 3 mln.
http://quotes.nasdaq.com/quote.dll?mode=frameset&kind=&symbol=VPHM&symbol=NVAX&symbol=INSM&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&selected=INSM&FormType=&mkttype=AFTER&pathname=&page=afterhours
I'm in AH at $2.17
Tomorrow's CC at 8am will provide more info.
"...FDA Approval of iPlex & Corporate Update Conference Call
Scheduled to start Tue, Dec 13, 2005, 8:00 am Eastern
Check back at the scheduled start time for
the audio link to appear in this spot.
Add this event to your Yahoo! Calendar Add This Event To Your Yahoo! Calendar
About Insmed Incorporated (NasdaqNM:INSM)
Insmed Incorporated, a biopharmaceutical company, engages in the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders. Its lead product includes recombinant human insulin-like growth factor-I bound to recombinant human insulin-like growth factor binding protein-3 (rhIGF-I/rhIGFBP-3), a Phase III clinical trial product, which would be used for the treatment of severe growth disturbance due to growth hormone insensitivity syndrome. The company's research and development stage products include rhIGFBP-3, for the treatment of various cancers; and INSM-18, for the treatment of various tumors. The company has strategic relationships with Fujisawa Pharmaceutical Co., Ltd.; Tzamal Pharmaceutical; Pharmacia, Inc.; and Avecia Limited. Insmed was incorporated in 1999 and is based in Glen Allen, Virginia...."
http://biz.yahoo.com/cc/8/63308.html
GLTA,
Gielda
Thanks for the post gielda2003 ! INSM at 2.32 AH now....
Things look good for tomorrow. I think it could run to just over 3.00 tomorrow if this news is as good as i think it is...then 4.00 longer term!
PLEASE VIEW THIS: http://shortsqueeze.com/index.php?PHPSESSID=36a200193090ec9c1951a0f2f1c398d4&symbol=INSM
It will take 9.8 days for short to cover their position...
Short interest is huge. Shorts will wake up tomorrow with a 60% loss and be forced to cover!
>:D
cal
Calven,
Many posters on Yahoo compare possible INSM run with the SPEX run. I know SPEX is low floater, but what is your take, if you don't mind.
Kindly appreciate your feedback,
Gielda
I expect 4.00 because of the short % of float..... >:D
3.00 would be tomorrow's "short term" target
Thanks calven.
:)
Gielda
I can't resist...Have market order to buy at the open..."thebioguy" estimates $5.75 this week...The market for for taller children is growing and may spread to non-clinically short...A designer drug for designing parents... ;D
;)
On fire today...
Good run @ all
Smoking in the pre-market......Hot
+46.31%.........Volume @......908,404
Yesterday's closing chart...
1.95 now....short term sell off - The shorts will ultimately make this move higher but for now im in the red....
In at 2.14....
I'm in at $2.00
Do you think it will go higher?
Don't understand what sort of manipulation it is ??!
I was thinking it to going higher then now !! - 1,88 -
-so, I'm waiting one day or two and going on HEB after- great potentiel -
Think they have huge news on Thursday...
Im in from 2.14 AH yesterday so yes i think it will go higher...lots of shorts left.
>:D
cal
Price range has been $1.80 to $2.04.
I am starting to worry about this on - after it gapped up to $2.04 at the open, it has mainly traded in the low $1.80's. I am not sure if this consolidation will lead to another surge, or whether this one is done. But if it makes it past $2.00 again, it should make another good move up. ;)
I almost purchased, but ran away quickly after some research.
100 million fully diluted shares outstanding and tons of converts ready to sell. Not to mention they need another very dilutive offering in the near feature. This sucker will have sellers everywhere for the foreseeable future.
I bought at the open at $2.00...I forgot the phrase,"buy on the rumor,sell on the news." I expected a short squeeze,which may have occurred after market yesterday and premarket today...I will hold,having faith in a big expanding market for the drug and the likelihood they will find a partner for manufacture and marketing rather than issue more stock... ;D
Would it be on green today after all that dillution ???
I think YES...'cause the day before closed @1,49...
We're just @ 1,64 now...so ???
We're gonna see....
Long 'n'short = STRONG BUY
http://www.docguide.com/news/content.nsf/news/8525697700573E1885256F390049E17F
Make your DD....probably will be bought by Big Boys...who knows ?!..
Attractive price now...nothing to be afraid by invest now...and probably bullish by next monthes...years...
They have exclusivity to sell their drug during 7 years...so ??
Take your parts in ...and...be cool about future ?! No ?
Buy bye
What do you make of the institutional trending?
http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_ticker?t=INSM&range=30&mgp=0&x=5&y=11&hdate=
what drug am i missing something>
is it a cancer drug?
please toss me the 411
Quote from: SeeingGreen on December 17, 2005, 02:34:16 PM
what drug am i missing something>
is it a cancer drug?
please toss me the 411
They are a research pharma who finally got a orphan drug approved...first product...first drug to [potentially] produce revenue....until this they had none...they just got approval. That's it. You might compare to TRCA, stock at 7 with a drug that is not as good. Analyst puts stock at 4 by 2008...however competitor already at 7+....so, you decide. I think its a buy, but its a long proposition....if you were looking to trade, I'd say buy a dip early next week, and hold to around 2 and sell it....other wise a long hold will probably get you a couple of dollars by middle of next year, minimum....the anticipate a mid-2006 launch so....there ya go.
EDIT: just to add theyve spent lots on research, they have substantial debt..so I dont know how attractive of a buyout opportunity it is...and with all that debt they dont have a lot of capital to bring a drug to distribute and market....these are major concerns with this stock....
Next big announcement for the stock MUST detail how and when the stock will be brought to market, or, who they will partner with to do so...I doubt a buyout...though, its possible, but expensive....for merely an ORPHAN DRUG (small market)
I have been following INSM since February. I am here to explain my understanding of what is happenning to the stock at the moment. This stock WILL NOT pop like SPEX did, as many people, including myself, thought it would on FDA approval. What I failed to factor into the equation, was the 42 million shares in warrants and converts that hit the market after the announcement last week. 28 million shares were traded on the 13th, most in the $1.80 to $1.85 range. The warrants were converitble at $1.29, $1,36, and the bonds at $1.71...many of those shares are now in circulation.
Volume has tailed off to a respectable level, and those traders who got in for a .50 pop are gone, as are a lot of people who got in at a buck and held for the news, which was not so long ago (August @ .96). So this stock needs to close above the $1.85 resistance to begin to move up. The churning should be over now, and a $1.90 to $2.00 close should happen Monday or Tuesday at the latest. The shorts aren't in it yet, to any degree, and those that are will be trapped shortly...pun intended.
I see a slow, steady climb in the short term to $3.50 , $4.00 by the end of January barring news of a production timetable or partner. The TRCA lawsuit for patent infringement has bee made moot by the orphan status, "not the same drug"...the "deceptive practices" suit is meaningless, and a desperate attempt by TRCA to further hamper INSM's meager capital by tying it up in legal fees.
This drug is going to market here now, and in the EU shortly...trade away...wild swings will be on news only, and will not be extreme...at least not like the NVAX spike or SPEX two day chart the first of December. Long term, you can't go wrong here, check out their pipeline..for day or swing trades...wait to get your money back...which will probably be this week, and go look somewhere else. This is a long term "accumulate and hold" stock...IMHO..with little but sunny days ahead of it, finally.
Regards and good trading,
vet24
P.S. A better "quick money" play would be to short TRCA.....
;)
Breakout confirmed...This may be a great long term investment,so I will hold.... ;D
I think we're gonna see stock going higher till now...
Listen...
19-Dec-2005
Sale of Equity
Item 3.02 Unregistered Sales of Equity Securities
Between December 13, 2005 and December 19, 2005, Insmed Incorporated received notices from holders of its 5.5% Convertible Notes due 2008 - 2010 electing to voluntarily convert $10,922,000 principal amount of Convertible Notes into 8,433,977 shares of common stock at the conversion rate of one share of common stock for each $1.295 in principal amount of the Convertible Notes. The Company also received $3,358,810 from warrant exercises that resulted in 2,374,234 shares of common stock being issued. 463,036 shares were issued at an exercise price of $1.71 and 1,911,198 shares were issued at an exercise price of $1.36.
The common stock issued upon the conversion of the Convertible Notes and the warrants was issued in reliance upon the exemption from the registration requirement of the Securities Act of 1933, as amended, provided for in
Section 3(a)(9) and Section 4(2) thereof and is all currently registered for resale by the holders pursuant to Insmed's Registration Statement on Form S-3 filed with the Securities and Exchange Commission on August 8, 2005 (the "Registration Statement").
Following the conversions described above, $11,438,000 principal amount of the Convertible Notes remained outstanding. In addition, because certain of the Convertible Notes were converted prior to the March 1, 2006 quarterly interest payment, the Company issued an additional 14,959 shares of common stock for the forfeited cash interest payment at a conversion price of $1.295. A summary of the terms of the Convertible Notes, including the conversion features and interest payments was previously provided in the Registration Statement and Insmed's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 16, 2005 (the "Current Report"). The form of the Convertible Notes was filed with the Current Report and the forms of the warrants were filed on Current Reports filed with the SEC on March 16, 2005 and November 10, 2004. The Registration Statement, the Current Report and the form of Convertible Note are each incorporated herein by reference.
It would appear about half of the warrant and bond conversions are fininshed and the new share "dump" on the market will slow substantially from here on out...
The 8k would bear this out, most of the $1.71 converts have restrictions on them.
We still need to close above $1.85 resistance to get on with the program, though...IMHO
vet 24 :)
Quote from: Malum2006 on December 18, 2005, 12:48:44 AM
They are a research pharma who finally got a orphan drug approved...first product...first drug to [potentially] produce revenue....until this they had none...they just got approval. That's it. You might compare to TRCA, stock at 7 with a drug that is not as good. Analyst puts stock at 4 by 2008...however competitor already at 7+....so, you decide.
Let me criticize your stock price comparison (4 to 7+). I'm assuming you know that isn't how you compare valuations. Why don't you try market cap? Now if you look at that, TRCA is still way ahead, but in my opinion that is a function of their much stronger balance sheet.
Steve
I'm still waiting for just that FIRST trade @ $1.86....
Volume has settled down and I would think this should trade 1.5-2 million shares a day once it breaks resistance and begins to move. With the larger float outstanding (concensus is 88-90 million) should be a fairly smooth, steady ride up without news. Slower than most would like, I think, but up just the same.
I look for a PR or two in January, one for the ramp up to production and the other for a partnership announcement...
Wishful thinking? Time will tell...
Regards,
vet24 :(
Hi,guys,
Do u still get positions ?
Cal,Set....r?
Yes I do...Why ??
- European/Global partner will soon be finalized.
From company comments we know they have been talking to at least three (several being more than two) potential partners and they hoped to finalize a deal by the end of the year.
While any deal was probably contingent upon an FDA approval, this may have been imposed by Insmed rather than potential partners, as an approval would require more attractive terms.
An interesting note is that this was originally a "European" partner in earlier presentations. In the Lazard presentation, this became a "European/Worldwide" partner.
This word choice interesting, indicating that a bigger player entered the game.
- On the pipeline front:
----Iplex label expansion clinical updates will be come early next year. Insmed is about to announce trials for abnormal retinal development/blindness in premature infants. This may be announced as early as January 2006.
Likewise, tissue repair, hip fracture, and extreme insulin resistance trials are all planned for the 1st half of 2006. By Fall, we should have an update on the HIV-Associated Lipodystrophy trial.
---- INSM-18 update is expected for the 2nd quarter of 2006. To define the maximum tolerated dose of INSM-18, this trial is for patients with relapsed prostate cancer. We do know informally, that this has been going very well.
----- BP3 trials expected in 2006. For several cancer indications, we could see some news on new trials in 2006.
2006 will probably be explosive if they realise what they have to do...
- European/Global partner will soon be finalized.
From company comments we know they have been talking to at least three (several being more than two) potential partners and they hoped to finalize a deal by the end of the year.
While any deal was probably contingent upon an FDA approval, this may have been imposed by Insmed rather than potential partners, as an approval would require more attractive terms.
An interesting note is that this was originally a "European" partner in earlier presentations. In the Lazard presentation, this became a "European/Worldwide" partner.
This word choice interesting, indicating that a bigger player entered the game.
- On the pipeline front:
----Iplex label expansion clinical updates will be come early next year. Insmed is about to announce trials for abnormal retinal development/blindness in premature infants. This may be announced as early as January 2006.
Likewise, tissue repair, hip fracture, and extreme insulin resistance trials are all planned for the 1st half of 2006. By Fall, we should have an update on the HIV-Associated Lipodystrophy trial.
---- INSM-18 update is expected for the 2nd quarter of 2006. To define the maximum tolerated dose of INSM-18, this trial is for patients with relapsed prostate cancer. We do know informally, that this has been going very well.
----- BP3 trials expected in 2006. For several cancer indications, we could see some news on new trials in 2006.
Looks like $2+ is just around the corner
http://stockcharts.com/gallery/?INSM
Readers be aware that wiseman213, bullissimo, vopiissimo, januaryeffect, and newnewbie may be the same entity or group. Wiseman213 was booted for registering as two users and then playing off one another as two different individuals, pumping low float stocks, all from the same ISP. Now it appears he (they) are back. Remember the movie "Sybil"?
[wiseman213, bullissimo, vopiissimo, januaryeffect, newnewbie and whomever else you may be lurking as]. You cheated, got caught, and are not trustworthy.
You have no credibility, no trust, you are being deceptive. You have also been reported to the moderator.
Quote from: JKN on December 29, 2005, 03:34:21 PM
Readers be aware that wiseman213, bullissimo, vopiissimo, januaryeffect, and newnewbie may be the same entity or group. Wiseman213 was booted for registering as two users and then playing off one another as two different individuals, pumping low float stocks, all from the same ISP. Now it appears he (they) are back. Remember the movie "Sybil"?
[wiseman213, bullissimo, vopiissimo, januaryeffect, newnewbie and whomever else you may be lurking as]. You cheated, got caught, and are not trustworthy.
You have no credibility, no trust, you are being deceptive. You have also been reported to the moderator.
Glad to see the forum police watching out for us. ;D Applaud
Quote from: stocks2watch2 on December 29, 2005, 03:49:26 PM
Glad to see the forum police watching out for us. ;D Applaud
Agreed. Applaud to JKN.
http://quotes.barchart.com/texpert.asp?sym=insm
Date Open High Low Last Change Volume % Change
12/29/05 1.91 1.97 1.87 1.93 +0.03 1799800 +1.58%
Composite Indicator
Trend Spotter TM Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold
Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 3622280
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 1657224
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 1546131
Overall Average: 96% - Buy
Price Support Pivot Point Resistance
1.93 1.82 1.92 2.02
very bullish technically, way under valued for a drug company just has FDA approved.
Averaged in - 1.98
Almost in the green. Hopefully it will run over 2.00 next week....
Seems to be creeping back up!
>:D cal
HOD at 2.19 guys....
This position looks like it could reach 2.30 soon.
Congrats
cal >:D
This was a very good looking Breakout with great follow through from
this Ascending Triangle (continuation) Pattern.
Volume: 4,803,981....... ;D
Avg Volume (3m): 1,438,260
Technicals
Most Actives
Percentage Gainer
Last Price Quote is:
21.30%above 13-day EMA
44.77%above 50-day EMA
RS Rating: 97
Fundamentals
Key Data:
Market Cap (M): $107.22
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: 03/15/2006
Last Analyst Rating: Buy
Yup you are right Therman... INSM really Hot!! ;) :D ;D
I'll take position tomorrow... goodluck all ;)
INSM & SUF
Notice something?... very similar uptrend (stacked G-patterns) ;)
No.. not good!! I don't like to see a Doji Star on the first day of my trade!! :(
So, i will sell this sucker @ open & buy something else.
IBIS top of the list ;)
How are we feeling about INSM now Gielda and Brandy!
Im up over 30%!!
>:D
;D
I first posted on the INSM hot board on August 17th..
My buyins were at $.91, $.93, $1.05, $1.17, $1.23, $1.32, $1.42, $1.71, $1.81, and now $2.55...I noted a definite lack of traffic on the board, so haven't been back much since...
Now that we have everyone's attention...
This is a long term play, in my book, although I have already taken 4 blocks off the table at over 140%. Todays block for sale is a mixed bag of buys that will only clear 80%+...
The swing traders will get their day shortly when the stock stalls between $3.50 and $3.90...
There are about 20 million shares out there (give or take 4 or 5 mil) that will double at these prices, profit taking will abound....the stock will stop and rest for a well desrved "breather" before it trudges dutifully up to $5...then the game changes...
My '06 target for INSM is around $20.00...I'm not a TA zealot, and use it only for timing analysis for entries/exits. INSM needs a partner purely for self defense purposes, the two names I'm hearing now are Genentech (YES DNA!!) and Novartis...I'd throw Pfizer into that mix just because PFE is hurting for a pipeline at the moment, and you can't find a better one anywhere...even if it is the same drug, being tested on multi-indications.
Currently price targets are $10-$12 tops around the analysts and chart watchers, that goes out the window with a partner.
Good to see some traffic on this mb for a change, even if it was a bit late getting here. Not to worry though, this stock is my "tortoise"...NVAX is my "hare" and the race to $20.00 is on...
Good luck to all, good trading...
Regards,
vet24
Always buy the pipeline. Once the FDA gave the orphan status it just woke the market up to INSM. I was surprised it didn't pop 40-50 % the day of approval. But it has been slowly and steadily climbing. Got in long ago and watched it for YEARS! Finally paying off. Now I'm watching GNBT. I'm in INSM to 20. Maybe this year. Seen it before at BLUD, HITK, MDCI, BDY. This is the year of BIO. It's been long time coming!
???Cut my position here in half in anticipation of the pullback. Loaded up some more NVAX awaiting bird flu funding news....didn't see the overall market correction coming, this hit almost everyone like a freight train at a crossing...but INSM is only down 10% in the past two days.
Buying opp here, InsMed is starting to provide some historical chart patterns to follow now that it's actually going somewhere. If the market drop levels off, I look for one or two more days in the $2.70 range...three max. Then it's on to $3.50 WITHOUT any news. We had a huge volume block changing hands for about a week in the $1.70 to $1.85 range, so I am still expecting the stock to stall at $3.50 for some profit taking...the good thing about the pullback and the correction occuring at the same time is the rally should continue for some time once it resumes, and there is no significant resistance above $3.50 at all.
My goals here are simple, build long term positions in INSM/NVAX by swing trading 40% to 50% blocks of each stock between the two of them, and buying call options as the opprtunities present themselves...until this week the plan was working just fine. One lesson learned though, no "sideline" money means no cash to buy into a huge opportunity like this...
P.S. Norvartis' name has come up in the rumor mill for an INSM partner....
Good luck and good trading, see you at $20.00....
Still holding all of my position. Averaged in from 1.98 Was a bit to aggressive early on with my 2.14 buy. Came to my senses and averaged in. Glad things worked out!
I dont plan on selling anytime soon...
cal >:D
Nice chart, nice volume this really could be the next VPHM.
8) I use shorter term charts for indicators when I'm considering entry/ exit points...5, 10, 20 day sma's and MACD/RSI for triggers. Right now, if you look at the 10 day, INSM's been bouncing off that, when it gets anywhere near it.
I think we continue consolidation at $2.70 on Monday, then resume the uptrend to the $3.50ish level, where the stock will consolidate again.
All in my humble opinion, of course...
Good luck..
vet24
Key technical support lines being tested!
I wont sell until that upsloping support line is broken...
cal >:D
In today @ 2.74. Let's see what happens.
Looks good. I'm also in @ 2.65.
(http://img93.imageshack.us/img93/2462/insm9rs.png)
::)
Got another wave of converts and warrants out of the way last week...6 million left in this batch ($1.295 to $1.71) nothing left other than those remnants and a batch of $4.90 conversion bond issues that you have to go back to 2003 to find in the SEC filings...
$3.50 is still my next "profit taking" stall target...may get more conversions there too, and the shorts may start jumping in along with the converts shorting "against the box" at that point. Could get to that target within a week, then spend another week there sorting that mess out. Should create a swing opportunity from about $3.70 exit to $3.00 reentry...I have one "mixed" block of shares that gets "ripe" there. Ripe being up 150%...
My aggregate now is $2.51, so nothing else will be sold under $5.00...that may take some good news to satisfy...and good news should be coming in batches by the end of the quarter. Phase II trial results, iPLEX launch schedule, marketing partner...etc...
Debt reduction here has been masterfully executed and will be good for the pps long term, people are starting to make comparisons to VPHM on the Yahoo board, time will tell.
Good luck,
vet24 ;)
Jumped in today at $2.79..............
Great thread here - I only just found it now as have been following David's - man I wish I saw it earlier ???
But am in as of Wed - at 2.62, so really good to hear some clear targets form people who know a lot about this one. Looking for first swing target around 3.35-3.50. Rock n roll ;D
.....Converts 'n' warrants are done...
Several days before, INSM hit 3,3$..
Now it's 2,53$...
-->today....for sure... INSM will be ON GREEN
LONG'n'STRONG INSM
Looks like INSM may have completed it's pullback. I think the huge sale this morning that made the low of the day may have made the bottom.
Our low today hit the trendline that starts Dec. 12 and gets another hit on Dec. 21. With RSI bottoming at 50 and the bounce off that trendline, INSM looks set for the next move upward. I bought this morning at 2.40.
Quoted from INSM Premium Board ;)
Quote from: Terlisa on February 04, 2006, 11:31:30 PM
**When +DI is on top, the trend is up go LONG baby ;)
**When -DI is on top, this indicates that bears are very strong.. Go SHORT my friends :D
The best time to use a trend-following method is when ADX is rising and is above the lower directional line. Those are two signs of dynamic trends ;)
I believe by combining MACD Divergence, Smoothed ROC & The Directional System you can catch an uptrend in the very beginning.. Don't pay attention too much on RSI indicator it will give you a premature buying & selling point ;)
Terlisa ;)
I was thinking of getting in on this one pretty soon... initially I was looking at 2.00 which is the 50dma and "psychologically strong". If it hadn't had that placement then I would have certainly gotten in on it at 2...
Now I'm not sure where it bounces... I think this is a great stock for a buy and hold, but as we all know, TA rules short term, FA long term, and I don't know how much pressure this will be under... When friday's placement news blows over, this will be a good buy, imho. This maybe at 2, or maybe a bit lower, imho, but the long term trend is up, imho.
GLTA
Consevative analyst C. E. Unterberg Towbin initiated INSM coverage on 4/11/06 with a BUY rating and a target price of $3.
Lazard Freres also has a BUY rating with a $4 target.
Other companies are researching INSM and I expect more coverage soon.
Institutions have been accumulating INSM shares heavily in recent months.
INSM pps has been under relentless manipulation for several weeks and now it is ready to roar...
INSM is the ONLY biotec trading under $2/share and with a market cap of less than $200M having:
--- One recently FDA-approved drug with orphan status (7 year protection) due for commercial launch in June 2006.
--- A huge pipeline of potentially blockbuster drugs addressing cancer, muscular disthrophy, diabetes, and other serious illnesses.
--- A solid balance sheet with over $60M in cash and no LTD.
REALISTIC 3-MONTH TARGET: $4 ++
******GREAT THREE MONTHS AHEAD******
...NEW FDA-APPROVED IPLEX COMMERCIAL LAUNCH IN MAY/JUNE..$$$$...ORPHAN STATUS
...SHAREHOLDERS' MEETING MID MAY
...IPLEX FOR INSULIN RESISTANCE PHASE 2 CLINICAL TRIAL RESULTS WILL BE PUBLISHES IN JUNE 2006 AT INTERNATIONAL ENDO CONFERENCE.
...IPLEX FOR MIOTONIC MUSCULAR DISTROPHY RESULTS.
...RESULTS FOR INS-18 ANTIBODY TO FIGHT PROSTRATE CANCER.
INSM has a solid balance sheet with over $60M in cash. In addition to that, INSM will launch iPlex, its first FDA-approved drug, in June 2006. Cash plus iPlex revenues will help push forward its HUGE drug pipeline.
DURING 2Q 2006 INSM WILL:
Accelerate the commercial launch Of iPlex, its first drug approved by the FDA (ORPHAN STATUS). The company plans to launch iPlex during 2Q 2006.
Continue pursuing the marketing authorization for IPLEX in Europe. The company will submit a formal application to the EMEA (the European equivalent of the FDA) shortly.
In mid June, INSM will present results of Phase 2 clinical trials using iPlex to treat Severe Insulin Resistance at the International Endo Society Conference.
Continue clinical studies of the various drug candidates like iPlex for Severe Insulin Resistance Resistance, iPlex for Miotonic Muscular Dystrophy, small antibody molecule INSM-18 currently in Phases I/II to combat prostrate cancer, and several other drugs.
The following are a few highlights related to INSM's drug pipeline
** On March 7, the Business Intelligence firm La Merie S.L. reported that antibodies are at the forefront of novel cancer therapeutics targeting the insulin-like growth factor-1 receptor (IGF-1R).The report states that INSM along with giant Pfizer are among the leaders in this promising oncology research area. INSM-18 is a dual inhibitor of IGF-1R and Her2/neu and is the only clinical stage IGF-1R small molecule antagonist (phase I/II in prostate cancer).
http://www.pr.com/press-release/7579
** INSM recently initiated Phase 2 Clinical Trials of iPlex for the treatment of Myotonic Muscular Dystrophy (MMD), the most common form of adult muscular dystrophy:
http://biz.yahoo.com/bw/060104/20060104005653.html?.v=1
Take a look at the current status of INSM's rich drug pipeline:
http://www.insmed.com/secondary.asp?...roductpipeline
CURRENT COMPANT FOCUS PER LAST CC....
iPlex Comercialization
iPLex Manufacturing
Pipeline Clinical Development
IPLEX COMERCIALIZATION:
iPlex will be comercially launched in June 2006.
INSM has hired top talent to assemble an impressive sales and marketing team.
New employees have an average of 17 years of experience in the area of pediatric endochrinology.
New employees were involved in 29 new product launches.
80% of the new sales force has direct experience with selling growth hormones and pediatric endochrinology.
The new sales force will concentrate their efforts to reach over 400 pediatric endochrinologists in the US.
IPLEX MANUFACTURING:
INSM owns an FDA-approved large manufacturing plant capable generating several hundred million dollars per year in revenues.
Having its own manufacturing plant, enables INSM to have complete control over all production issues including quality control, operational flexibility and efficiency, safety and environmental compliance, etc..
INSM is currently working on an iPlex formulation that is stable at room temperature. This product will be launched in early 2007. Currently iPlex (and competing products) require that they be stored in a refrigerator prior to use. This will be a huge advantage of INSM's product over existing competitors not havin g that capability.
PIPELINE CLINICAL DEVELOPMENT
INSM will be conducting clinical trials to extend its iPlex patient population from 6,000 to over 30,000 by addressing other conditions affecting children with IGF-1 defficiency.
June 2006 presentation of results of Phase II iPlex clinical trials for Severe Insulin Resistance in Type 1 diabetics (Endo show)
Continue educating medical and patient population about the benefits of iPlex in 7 shows/conferences in the next 3 months.
DO YOUR DD!!
I agree with you on INSM at $10 in the future. I think it is the next VPHM. I only have 7000 shares and would have liked to add more when it was down to $2.20
INSM should break a couple of resistance levels today.
Still very...very cheap at these prices.
Strong start for INSM. My guess is that it will close aroud $2.7 today. We'll see.
Bad market???.....not for INSM
http://stockcharts.com/gallery/?insm
INSM is looking really strong. The last two hours of trading will be PANDEMONIUM. I just can't understand why people wait until the last minute to buy and they end up paying a lot more for their shares.
Applaud Terabemo, you said whatch for the run, and for sure this pre earns run delivered.
Lets see how the post earns reaction goes.....
So honestly, how many of you guys are planning on selling before the CC tomorrow? I believe this stock will be great in the long term but I sure have crappy luck holding through earnings/CCs.
GLTA
hi,
haven't posted for a while but i will definetly be selling before close. it could be great but could be is too much of a gamble for me.
i was thinking about holding through but have been burnt more times than i have won,
good luck to those holding through,
maxi
I plan on selling half..
MACD early cross over. Radar it. >:D
I held INSM through its pullback just recently and plan to ride this through the earnings, the chart has shaped up nicely to attack the $3 area. Volume hasn't really kicked in yet, so the real action for sure will happen once the 'news' is out.
I normally don't hold through earnings, but this has come back so strong from the 50sma that I'm willing to let it work.
Good luck to all ;)
Thanks for the input, everyone. I'm still torn. Let's see what tomorrow brings.
Today's action is great.
Commenting on the earnings tomorrow, as they don't have any real earnings, probably we shouldn't worry toomuch :)
All I look forward is for the future plans and guidence.
Thanks,
mads888
Quote from: terabemo on March 01, 2006, 10:25:47 AM
INSM is looking really strong. The last two hours of trading will be PANDEMONIUM. I just can't understand why people wait until the last minute to buy and they end up paying a lot more for their shares.
Terabeamo - the stock went up 2 cents in the last 2 hours of trading and stayed in a range the whole time between 2.61 and 2.65. That's pandemonium? LOL!! >:D
What are your thoughts on TRBM (Terabeam)? You haven't posted on that thread in a while. You were as excited about TRBM as you now are about INSM but then one day you were gone and suddenly pumping a new stock. What's up?
INSM should have a great Thursday and even better Friday IMO. If the CC is bullish and answers most questions (adequately) about the iPlex launch, the ongoing clinical trials, the current/future financial picture, INSM should certainly see new 52-week highs. The only thing holding this stock down is UNCERTAINTY.
Good luck to all..
Lucas (Re: TRBM). TRBM is a 6 to 12 month hold of mine. I added more at $3.92. I like the company and its potential A LOT. Thank you for asking.
yesssss....we will have a beautiful Thursday...Friday...
Look @ that news(we will have it after hours= good sign!)
watch it on Yahoo --> Q4 2005 Insmed Incorporated Earnings Release - After Market Close
CCBN (Thu 7:07am)
Have a good day Guys...
hi,
why is it a good sign to have the news after hours? just curious.
sold thiis morning 269.
glta,
holding,
maxi
Sold half @ 2.59. Let's hope the market likes this CC!
Bought for 2.40 about a month ago.
I ended up holding my shares. The CC was quite positive. Here's hoping for an upgrade in the next month.
What's happening here?
Is the offering on Monday what was already scheduled, or an additional offering?
Last chance to buy INSM under $2.2 IMO. We'll see...............
INSM is bouncing nicely after hitting a brick wall resistance at $2.12.
I expect that INSM will start moving up strongly starting tomorrow.
The great ELN news will fuel a biotec rally tomorrow. Plus, the GOOG blues will be over tomorrow. The Nasdaq is oversold and it will bounce hard this week.
calm....
we're waiting ...
Have a good day.. ;)
Bought in this morning at 2.21 (as per post on 1,000,000 board). Lots of people in my trading group are in this at 2.2 as well... This will bounce in the next few days imo.
glta
g
I agree. I see $2.4++ easily next week. Once it gains momentum this time INSM will be unstoppable IMO with most of the negativity far behind now.
INSM is making noise in the cancer therapy sector:
Antibodies Are The First Wave Of IGF-1R Antagonists For Cancer Therapy
Main Category: Cancer/Oncology News
Article Date: 07 Mar 2006 - 0:00am (UK)
BARCELONA, Spain - The Business Intelligence firm La Merie S.L. reported today that antibodies are at the forefront of novel cancer therapeutics targeting the insulin-like growth factor-1 receptor (IGF-1R). Pfizer is leading the field with the fully human IgG2 antibody CP-751,871 under investigation for multiple myeloma and advanced non-small cell lung cancer. Five other companies are closely following with antibody projects. Only six companies are currently visible with small molecule inhibitors targeting the IGF-1R tyrosine kinase which are not always selective for IGF-1R. INSM-18 from Insmed and the University of California San Francisco is a dual inhibitor of IGF-1R and Her2/neu and is the only clinical stage IGF-1R small molecule antagonist (phase I/II in prostate cancer). These results and more were found in a search conducted by La Merie Business Intelligence published in the March 6 issue of R&D Pipeline News, edited by La Merie. The competitor analysis of CB1 antagonists can be acquired at www.pipelinereview.com, La Merie's News Center and Online Store.
IGF-1R
Although the IGF-1 receptor was first cloned in 1986, it was the success of targeted drugs such as trastuzumab and imatinib that tyrosine kinase inhibitors and growth factor receptor blockers became hot targets. Now companies are aggressively pursuing compounds that target IGF-1R. Other reasons for the long delay in bringing compounds against IGF-1R into the clinic may be: 1) the fear that blocking IGF-1R in cancer therapy would also block the insulin receptor and signaling (70 % homology with IGF-1R) and, thus might be diabetogenic; and 2) the expression of IGF-1R in normal tissue throughout the body. Aventis selected an antibody which does not bind to the closely related insulin receptor. However, preclinical data indicate a limited spectrum of tumor cell lines against which the antibody was effective.
While antibodies are exquisitely selective inhibitors of the IGF-1R function by inducing rapid internalization and down regulation of the receptor, small molecule tyrosine kinase inhibitors suffer from a lack of selectivity because of binding to a well conserved site. In fact, several of the IGF-1R tyrosine kinase inhibitors in development are dual inhibitors, and in general do not lead to internalization and downregulation. Nevertheless, small molecule IGF-1R inhibitors offer the advantage of the ability to control the duration of drug exposure in contrast to long-acting antibodies.
Apart from antibodies and small molecules, there are individual approaches using peptides, proteins or antisense oligonucleotides to antagonize IGF-1R. The latter one has been evaluated as a topical cream to treat patients with psoriasis, but needs further dose optimization.
About R&D Pipeline News
R&D Pipeline News is a premier information source about research and development projects in the pipeline of the biopharmaceutical industry. The periodical is directed to all stakeholders in R&D. The weekly publication comes in a rapid- and easy-to-screen tabular format and provides access to the original information source via hyperlinks. R&D Pipeline News covers all relevant treatment modalities and is directly delivered to the desktop via e-mail. More information about the journal, a free trial and subscriptions are available via La Merie's Business Intelligence Center www.pipelinereview.com.
About Pipeline Review.com
PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on R&D in the Biopharmaceutical Industry. Visitors of PipelineReview.com will find R&D relevant press releases and can receive selected R&D news from one or more of the site's News Channels. A free R&D Newsletter conveniently brings via e-mail a daily selection of the most interesting news from biopharmaceutical R&D. For more information visit www.pipelinereview.com.
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit http://www.lamerie.com
http://www.medicalnewstoday.com/medicalnews.php?newsid=38971&nfid=rssfeeds
This is great!
On March 7, the Business Intelligence firm La Merie S.L. reported that antibodies are at the forefront of novel cancer therapeutics targeting the insulin-like growth factor-1 receptor (IGF-1R).
The report states that INSM along with giant Pfizer are among the leaders in this promising oncology research area. INSM-18 is a dual inhibitor of IGF-1R and Her2/neu and is the only clinical stage IGF-1R small molecule antagonist (phase I/II in prostate cancer).
http://www.pr.com/press-release/7579
Where are we going now??...have we finaly touched the bottom...
I'm expecting a rebound this week...
Cheers,
-Doyle-
LAZA (Lazard..the underwriter) is providing strong support today. Every time the shorts push the pps down, LAZA shows up with a huge bid.
The street seems to have liked the fact that INSM netted about $5M more than it was originally estimated. We'll see if that continues tomorrow.
News out....
Are we going to run now ?? (!)
Insmed Completes $46 Million Public Offering
Wednesday March 15, 4:05 pm ET
Underwriters Exercise In Full Option to Purchase Additional Shares
RICHMOND, Va.--(BUSINESS WIRE)--March 15, 2006--Insmed Incorporated (NASDAQ:INSM - News) today announced that the underwriters of its previously announced public offering, have exercised in full the option to purchase an additional 3,000,000 shares of Insmed's common stock. The offering of 23,000,000 shares of common stock, including the over-allotment shares, closed on March 15, 2006. All of the shares in the offering were sold by Insmed.
ADVERTISEMENT
Insmed received net proceeds of approximately $42.8 million from the offering which it plans to use for working capital and for other general corporate purposes, including the continuing commercial launch and manufacturing of IPLEX, the pursuit of marketing authorization for IPLEX in Europe and clinical studies.
-Cheers-
Doyle
With most os the negativity behind, INSM is starting to move. I believe we are on a path to new 52-week highs with all the great stuff coming up in the next three months......
EMEA application, clinical trial updates, iPlex launch...etc.
INSM is inching up a few cents a day. Great entry point. It has not REALLY started to move up yet. But when it does, it will do a GNBT....and will be able to support higher prices.
Those buying GNBT today will become major bagholders. The company will start human trials in late 2006. By the time they develop something the bird flu hype will be long gone....just like SARS.
The scary thing is that GNBT lost $14.4M last quarter and only have $15 in cash left. What do you think it's going to happen??...Another stock sale.....and I don't think anyone would offer more than $2 for those shares. I'd be very careful with GNBT.
INSM has survived a rush of negative publicity lately just for being professional and for providing maximum transparency.
For instance, the announcement yesterday, that there was a "going concern" clause in the last 10-Q, and that it has been quickly addressed by obtaining $42.8M recently, is something that most biotecs don't do. Take GNBT, for instance, if you read their 10-Q, they have the "going concern" clause in every quarter. But they never release that information to the public. They never even release formal earnings PR's. Heck, most biotecs have similar clauses on their 10-Q/K's and never disclose that.
Now you know what happened yesterday, most of the over-reaction was caused by the criminal AP article that did not mentioned a word that INSM already addressed the issue. INSM has been penalized for being up and up with everything.... good or bad.
FYI, INSM has one of the highest Corporate Governance Quotient (CGQ) in the industry. As of March 1, 2006 INSM's CGQ was better than 95.7% of CGQ Universe companies and 86.7% of Pharmaceuticals & Biotechnology companies. As a comparison, GNBT's is the lowest (in the low teens).
I can sleep at night holding a bunch of INSM shares because management is doing the right things for the long-term appreciation of my investment in this company.
- INSM WILL LAUNCH IPLEX, ITS FIRST FDA-APPROVED DRUG, IN 2Q 2006.
- Also in June 2006, INSM will present results of Phase 2 using iPlex to treat Severe Insulin Resistance (of of many new applications of iPlex). This is a multi-billion dollar market
- INSM HAS a STRONG BALANCE SHEET....$61M IN CASH. No further dilution this year. Will start generating revenues in 2Q 2006.
- RICH DRUG PIPELINE ADDRESSING AILIMENTS FROM CANCER, TO INSULIN RESISTANCE, TO MUSCULAR DISTHROPHY, TO MUSCLE/BONE WEAKNESS, TO HIV......etc...etc....
++++++++++INSM will use its cash to:+++++++++
*** Accelerate the comercial launch and manufacturing of iPlex, its first drug approved by the FDA. The company plans to launch iPlex during 2Q 2006.
*** Continue pursuing the marketing authorization for IPLEX in Europe. The company will submit a formal application to the EMEA (the European equivalent of the FDA) any day now.
*** Continue clinical studies of the various drug candidates like iPlex for Severe Insulin Resistance, iPlex for Miotonic Muscular Dystrophy, small antibody molecule INSM-18 currently in Phases I/II to combat prostrate cancer, and several other drugs.
The following are a few highlights related to INSM's HUGE drug pipeline
** On March 7, the Business Intelligence firm La Merie S.L. reported that antibodies are at the forefront of novel cancer therapeutics targeting the insulin-like growth factor-1 receptor (IGF-1R).The report states that INSM along with giant Pfizer are among the leaders in this promising oncology research area. INSM-18 is a dual inhibitor of IGF-1R and Her2/neu and is the only clinical stage IGF-1R small molecule antagonist (phase I/II in prostate cancer).
http://www.pr.com/press-release/7579
** INSM recently initiated Phase 2 Clinical Trials of iPlex for the treatment of Myotonic Muscular Dystrophy (MMD), the most common form of adult muscular dystrophy:
http://biz.yahoo.com/bw/060104/20060104005653.html?.v=1
......MARCH 2, 2006 BUSINESS UPDATE.
Immediate Company Focus: Three major areas:
iPlex Comercialization
iPLex Manufacturing
Pipeline Clinical Develoment
DETAILS BELOW:
http://insmtotewnty.blogspot.com/
DO YOUR DD
INSM TO BE HONORED ON APRIL 24:
NORD Honors Companies and Individuals at 2006 Tribute Banquet
Representatives of patient organizations, the research community, government agencies, and health-related industries will gather to honor outstanding contributions to the development of treatments for rare diseases at the 2006 NORD Tribute Banquet on Monday, April 24, in Washington, DC.
Each year, NORD honors individuals and companies for milestones in the development of diagnostics and treatments for rare diseases. In addition, NORD honors government officials who have played key roles during the year in improving the lives of people affected by rare diseases.
This year, the NORD Banquet will include a special tribute to the U.S. Food and Drug Administration (FDA) in honor of its 100th anniversary. The FDA and its staff play a crucial role in determining the safety and effectiveness of new drugs, biologics, and medical devices for rare disorders.
The Tribute Banquet will be held at the Capital Hilton Hotel in Washington, DC. For further information about reservations, contact Donna Bolton at NORD (203 744-0100 or
[email protected]) or download forms from this Web site.
Honorees for 2006 are:
The U.S. Food and Drug Administration, in honor of its 100th anniversary
The Biotechnology Industry Organization (BIO): (To be represented by James C. Greenwood, President & CEO)
The Pharmaceutical Research and Manufacturers of America (PhRMA): (To be represented by Billy Tauzin, President)
The Generic Pharmaceutical Association (GPhA): (To be represented by Kathleen Jaeger, President)
John J. McCormick, MD, Deputy Director, Office of Orphan Products Development, U.S. Food and Drug Administration
BioMarin Pharmaceutical Inc., for the development of Naglazyme, a treatment for Maroteaux-Lamy disease (MPS type VI)
Celgene Corporation, for the development of Revlimid, a treatment for myelodysplastic syndrome
Insmed, Inc., for the development of IPLEX, and Tercica, Inc., for the development of Increlex, two new treatments for the treatment of severe primary IGF-1 deficiency (e.g., Laron dwarfism)
Novartis Pharmaceuticals, for the development of EXJADE, a new oral treatment for chronic iron overload due to blood transfusions
http://www.rarediseases.org/briefs/2006_trib_banq_hnrs
>:(
--> 'time to UP !
Very very soon...they'll launch their product..then...--> $$$$$
2$ is cheap !...in a near future( I hope really )...we will see 4$ (a Minimum...)
Good price..
See ya later
'Doyle
It is likely that some of the GNBT money will take position in safer, financially stronger, and fundamentally superior INSM next week. Next week will not be pleasant for GNBT holders...unfortunately.
Hi Terabamo...
INSM would probably announce a new partner for the launch of Iplex @ the end of Quarter...don't forget it...
Also, we will have news from the Court on 5th April ( 'm a little afraid about that..)
Have a good day 'man
cheers
If you have not purchased INSM in the $1.8's and $1.9's you will not be a happy camper when this gem hits $4++ in June of 2006. We might even see $3+ in April since the company is slated to present results of two clinical trials. I am everaging down like crazy even though I seldom agree with the principle of averaging down.
INSM IS BREAKING OUT!!!
Keep an eye on INSM. We have some buyers now.....once it goes over $2 it will run hard.
This stock had a share of bad stuff against it and it held it strong despite a valiant effort by stubborn (and suicidal) shorts. There are too many good things to list coming up and with the slightest good news this one will rocket.
Many biotecs do rocket but they don't the strong fundamentals that INSM has.
still waiting it to go up....with a valiant effort :-X !!!
Sure about the pipeline... ;)
so what the prob's ! :(
This stock must be @ minimum 3$ ! :'(
still an opportunity...(1.9) :o
Wait'n'see.... ::)
INSM BOUNCING FOLKS...THIS IS A ROCKET ABOUT TO TAKE OFF!!!
INSM should bounce from here. Diminishing results for shorts.
Great 3 months ahead....$4 in June 2005 IMO
Can anyone help verify a CEUT upgrade to $3?
Insmed, Inc.-INSM initiated with a Buy & $3 target@CEUT
C.E. Unterberg expects the IPLEX launch to begin in Q2 and they think sales could reach $200M in 2010.
INSM is jiggy in premkt but vol not that compelling.
tia and gl
Found it.
http://www.briefing.com/Investor/Public/MarketAnalysis/Calendars/UpgradesDowngra des.htm
;)
http://www.3stocksonfire.org/trading/index.php?topic=4489.new#new
Analyst Unterberg Towbin started INSM coverage today with BUY rating with a price target of $3. The other analyst has set the price at $4 within a year. Other companies are researching INSM and I expect more coverage soon.
INSM has been under relentless manipulation for several weeks and now it is ready to roar...
REALISTIC 3-MONTH TARGET: $4 ++
******GREAT THREE MONTHS AHEAD******
...NEW FDA-APPROVED IPLEX COMMERCIAL LAUNCH IN MAY/JUNE..$$$$...ORPHAN STATUS
...SHAREHOLDERS' MEETING MID MAY
...IPLEX FOR INSULIN RESISTANCE PHASE 2 CLINICAL TRIAL RESULTS IN JUNE.
...IPLEX FOR MIOTONIC MUSCULAR DISTROPHY RESULTS.
...RESULTS FOR INS-18 ANTIBODY TO FIGHT PROSTRATE CANCER.
...HUGE PIPELINE...CANCER..DIABETES..MD..HIV
...ONLY $180M MARKET CAP
..........SUPER UNDERVALUED!!!!!
My Target: $3.5 - $4.5 by the end of June 2006
INSM has a solid balance sheet with $60M in cash, and a solid plan going forward.
INSM PLANS TO USE THE FUNDS TO:
- Accelerate the comercial launch and manufacturing of iPlex, its first drug approved by the FDA. The company plans to launch iPlex during 2Q 2006.
- Pursue marketing authorization for IPLEX in Europe. The company will submit a formal application to the EMEA (the European equivalent of the FDA).
- Continue clinical studies of the various drug candidates like iPlex for Severe Insulin Resistance, iPlex for Miotonic Muscular Dystrophy, small antibody molecule INSM-18 currently in Phases I/II to combat prostrate cancer, and several other drugs.
The FDA approval of iPlex to treat children with growth problems resulting from IGF-1 defficiency has brought to the forefront INSM's impressive pipeline of drug candidates.
The following are a few highlights related to INSM's drug pipeline
** On March 7, the Business Intelligence firm La Merie S.L. reported that antibodies are at the forefront of novel cancer therapeutics targeting the insulin-like growth factor-1 receptor (IGF-1R).The report states that INSM along with giant Pfizer are among the leaders in this promising oncology research area. INSM-18 is a dual inhibitor of IGF-1R and Her2/neu and is the only clinical stage IGF-1R small molecule antagonist (phase I/II in prostate cancer).
http://www.pr.com/press-release/7579
** INSM recently initiated Phase 2 Clinical Trials of iPlex for the treatment of Myotonic Muscular Dystrophy (MMD), the most common form of adult muscular dystrophy:
http://biz.yahoo.com/bw/060104/20060104005653.html?.v=1
** In June 2006, INSM will present results of Phase 2 using iPlex to treat Severe Insulin Resistance at the International Endo Society Conference.
......MARCH 2, 2006 BUSINESS UPDATE.
Immediate Company Focus: Three major areas:
iPlex Comercialization
iPLex Manufacturing
Pipeline Clinical Development
IPLEX COMERCIALIZATION:
iPlex will be comercially launched in June 2006.
INSM has hired top talent to assemble an impressive sales and marketing team.
New employees have an average of 17 years of experience in the area of pediatric endochrinology.
New employees were involved in 29 new product launches.
80% of the new sales force has direct experience with selling growth hormones and pediatric endochrinology.
The new sales force will concentrate their efforts to reach over 400 pediatric endochrinologists in the US.
IPLEX MANUFACTURING:
INSM owns an FDA-approved large manufacturing plant capable generating several hundred million dollars per year in revenues.
Having its own manufacturing plant, enables INSM to have complete control over all production issues including quality control, operational flexibility and efficiency, safety and environmental compliance, etc..
INSM is currently working on an iPlex formulation that is stable at room temperature. This product will be launched in early 2007. Currently iPlex (and competing products) require that they be stored in a refrigerator prior to use. This will be a huge advantage of INSM's product over existing competitors not havin g that capability.
PIPELINE CLINICAL DEVELOPMENT
INSM will be conducting clinical trials to extend its iPlex patient population from 6,000 to over 30,000 by addressing other conditions affecting children with IGF-1 defficiency.
June 2006 presentation of results of Phase II iPlex clinical trials for Severe Insulin Resistance in Type 1 diabetics (Endo show)
Continue educating medical and patient population about the benefits of iPlex in 7 shows/conferences in the next 3 months.
DO YOUR DD
other indications...
Posted by: coinstarz (Investors Hub)
"Partial Lists of Health Insurance that cover iPlex."
CIGNA HealthCare
http://www.cigna.com/health/provider/pharmacy/coverage_positions/ph_6108_coverag epositioncriteria_me...
BCBSNC
http://www.bcbsnc.com/services/medical-policy/pdf/treatment_for_severe_primary_i gf-1_deficiency.pdf
inter mountain healthcare
http://www.intermountainhealthcare.org/xp/public/documents/hp/increlex.pdf
Michigan Health Insurance Company (M-Care)
http://www.mcare.org/include/template.cfm?ID=1164
connecticare
http://www.connecticare.com/globalfiles/pharmacycentral/SpecRXlist.pdf
Iowa Medicaid
http://www.iowamedicaidpdl.com/index.pl/informational_letters/informational-lett ers/informational-le...
Caremark and PacificSource
http://www.pacificsource.com/PDFs/Rx_Preauth.pdf
Great-West Healthcare
http://www.greatwesthealthcare.com/Preferred%20Drug%20Lists/Document%20Library/m c153.pdf
K A N S A S
http://www.da.ks.gov/hpf/medicalpolicy/DUR/Agendas/030806.pdf
Harvard Pilgrim
http://www.harvardpilgrim.org/portal/page?_pageid=253,220062&_dad=portal&_schema =PORTAL
FIRSTCARE
http://www.firstcare.com/prefdrug/index.asp?drugletter=I
http://www.firstcare.com/pdf/3tierDCL.pdf
bcbsne
http://www.bcbsne.com/members/_PDF/PrimeRxSpecialy%20List%20FINAL%201-31-06.pdf
LONG INSM XXXX
INSM IS FORMING A SOLID BASE ABOVE $1.75.
http://stockcharts.com/gallery/?INSM
ONCE INSM BREAKS $1.8 IT WILL LIKELY START ITS NEW RUN TO POSSIBLY $4++ IN JUNE
CEUT COVERAGE RESEARCH 4/11/06....INSM...BUY....TARGET: $3
Insmed, Inc. (INSM5,6,7,8,9 $1.69) - Buy
Growing Potential – Initiating with Buy Rating
Initiating coverage of Insmed with a Buy rating.
Insmed's lead product, IPLEX, was approved in December 2005, for the treatment of severe primary IGF deficiency. Though it has not launched yet, we expect launch to begin in 2Q:06. We believe it will soon lead the IGF-1 market over its competitor Tercica's Increlex (which was launched in January 2006) given its favorable safety profile as well as added convenience. We believe the initial worldwide sales for IPLEX and Increlex growth hormone revenue may represent a combined opportunity of roughly $10-15MM in 2006 growing to $200MM in 2010.
We highlight Insmed's pursuit of an indication for HIV lipodystrophy. We estimate the number of patients with HIV lipodystrophy could be as high as 800,000. Insmed holds a key advantage over its competitors in that IPLEX can safely be used in the nearly 50% of HIV lipodystrophy patients who are insulin resistant. IPLEX would step easily into this role to fulfill the unmet need for these patients. Though this program is in the early stages and we would not expect to see an FDA filing until 2009, we would point to this as the key driver for the name as a long-term buy and hold story.
We believe INSM's shares are best suited for investors seeking private equity type returns with the stomach necessary to deal with nearer-term volatility as litigation matters are worked through. Furthermore, a longer-term time perspective permits investors to look past the somewhat limited initial market opportunity for IPLEX, and ahead to significantly larger potential market opportunities, including those beyond short stature.
We arrive at our 12-month price target for INSM of $3.00 by averaging valuation ranges arrived at both under a multiple of revenue and multiple of earnings perspective. Our target represents potential upside of more than 75% to INSM's current levels.
Upcoming events for INSM include an Unfair Business Practices Judgement Hearing on April 15 and a Markman hearing on May 19. Historically, Markman hearings have been used to assess a judge's bias in a particular patent case and to review procedural issues. In this case, the judge, Judge Claudia Wilkens, has not tried many patent cases. We note that this is more a formality for Insmed and would not assign it much weight as a catalyst.
The major risk for Insmed stems from the patient litigation with Tercica and Genentech. In December 2004, Tercica and Genentech began to file a series of complaints against Insmed. A negative decision could have a major impact on Insmed as it could potentially eliminate its only commercialized product. However, we add that the risk of this outcome is not as likely as a monetary settlement. Additional risks for Insmed include the successful launch of IPLEX as well as the company's inability to differentiate IPLEX from TRCA's Increlex. There is also risk in the inability to successfully develop and commercialize other pipeline products. For greater discussion of risks, see the body of our report as well as the company's reports filed with the SEC.
Andrew Fein
Equity Research -- Biotechnology
Quote from: terabemo on March 02, 2006, 07:36:11 AM
Lucas (Re: TRBM). TRBM is a 6 to 12 month hold of mine. I added more at $3.92. I like the company and its potential A LOT. Thank you for asking.
Terabeamo - TRBM tanked today. Your thoughts on their 1st quarter guidance?
INSM is looking good today. Last trade $1.88 up 8c.
Re: TRBM, I had a feeling that something was wrong because the way that it was trading. I averaged down today. Good long-term hold.
INSM IS MOVING UP NICELY NOW... >:D
It was really time !
'nice...
8)
What's up Doyle where r u?
INSM still bearish a bearish stock... I can't see any confirmation of a trend change ;)
Goodluck Doyle....
INSM receives an important recognition today.....
NORD Honors Insmed for Role in Developing Treatments for Rare Diseases
Tuesday April 25, 9:30 am ET
Company Saluted for Research in Treating Children With Extreme Short Stature
RICHMOND, Va., April 25 /PRNewswire-FirstCall/ -- Insmed Incorporated (Nasdaq: INSM - News) was honored by the National Organization for Rare Disorders (NORD) last night at its annual Tribute Banquet for the development of IPLEX(TM) (mecasermin rinfabate (rDNA origin) injection) for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. IPLEX was approved by the United States Food and Drug Administration in December 2005 as an orphan drug.
"For many years we've recognized the need for treatment for Primary IGF-1 deficiency, but few companies were willing to commercially develop insulin- like growth factor until now. IPLEX(TM) is a significant medical advancement worthy of recognition and we thank Insmed for this important contribution," said Abbey S. Meyers, President of NORD.
"We applaud NORD's longstanding tradition of recognizing those that dedicate their life's work to finding treatments for rare diseases, and we are delighted to be included in this celebration," said Ronald D. Gunn, M.B.A., Executive Vice President and Chief Operating Officer of Insmed. "IPLEX(TM) is the culmination of over 20 years of dedicated research and development, and represents a breakthrough in IGF-1 replacement therapy, with potential benefits in several additional rare diseases with unmet medical needs."
About IPLEX
IPLEX, a complex of rhIGF-1 and rhIGFBP-3, is the only once-daily IGF-1 replacement therapy and the only therapy that provides both IGF-1 and IGFBP-3 that is approved by the FDA to treat children with severe Primary IGFD. The drug, expected to launch during the second quarter of calendar year 2006, is also being studied for various other indications with unmet medical needs including extreme insulin resistance, myotonic muscular dystrophy and HIV Associated Adipose Redistribution Syndrome (HARS).
About the Condition
Severe Primary IGFD is a genetic condition in which patients do not generate sufficient quantities of insulin-like growth factor-I (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), two key proteins involved in mediating the effects of growth hormone. Patients with severe Primary IGFD present with extreme short stature (height standard deviation score, SDS < -3) and an extremely poor prognosis for adult stature. Whereas prepubertal height SDS can range as low as -9, a blunted pubertal growth spurt is usually apparent, resulting in adult height that is typically 5-12 SD's below the normal population (adult height between 100 and 140 cm). The profound short stature in patients is often associated with severe psychosocial problems.
About Insmed Incorporated
Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit http://www.insmed.com.
Quote from: Terliso on April 23, 2006, 01:42:40 AM
INSM still bearish a bearish stock... I can't see any confirmation of a trend change ;)
What about now?
thx...Jody
Lets listen to this first ;)
Q1 2006 Insmed Incorporated Earnings Release - After Market Close
Heres what were looking for guys - we need a break of that downsloping trendline! >:D
sure Calven...we need it..and with looking the Yahoo mb..guys seem to be really optimistic ...
we will see the next few days...
This company has a lot ( in its pipeline...with commercial launch of IPlex very soon)
There's a lot of interset in Iplex,...the company has now $59.5 M in cash till 2007...
---> It has to move up
one of the most recommended message is this one :
http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=1600811390&tid=insm&sid=1600811390&mid=93114
....( this is the yhoo mb, don't forget it...)
'm waiting 4 a nice move
D. ::)
CC was not bad at all yesterday - the link that Doyle posted basically highlights all the positives form it. However they were a little light on details about certain things - they said that IPLEX will be launched on schedule in the next several weeks, which sounded like "towards the end of q2" - so any launch is unlikely to have an impact on next Qs revs. They were also unwilling to make any forecasts on sales or impact of IPLEX on 2006 revs, preferring to "wait and see" once it is released and have some more market data on demand, which I suppose is reasonable, but still leaves uncertainty as to how well it will be adopted. Finally, they were unwilling to give any further details about the lawsuit with TRCA, beyond stating that the hearing date is set for November and that they believe they have a strong case. Again a bit more uncertainty.
I also want to see INSM get going, hey it was my pick for the contest, but i don't really think it will kick off unitl they start selling it and analysts get a better idea of future revenue estimates. But I think the positive news from the CC, namely the launch is on track, they have manufacturing, sales and marketing teams going at full speed, should get it back above 2.00. The bigger move may still be some time away though.
down over 5% today...up almost 8% in AH
Long term here....
Hey 422,
I'm long term long here too, and bought back in a couple weeks ago, because IPLEX launch is definitely going ahead and everything looks positive post CC except for the share price! :P
So I think we probably better think about making some trading plans here as its certianly not doing what I expected.
From the chart I see the key support area as between 1.64 and 1.66. We have an ascending trendline off the sept-nov consolidation pre-breakout that looks to be coming in just below 1.64 right now, the most recent low was 1.65, which also corresponds to the spike-highs in sept and oct at 1.63 and 1.64 respectively, and the 200MA is currently sitting at 1.66. So I reckon a reasonable stop would be around 1.62-1.63, representing about a 6.8% loss on my buy at 1.75 (the only bummer is that because I am using a UK brokerage and the $ has been taking a nose-dive recently, I am already down 5% when the pps is exactly at my buy point ??? what gives eh?).
Don't really see any reason whiy it should head down there, with everything expected in the next month or two, but gotta plan for all eventualities and stick with that plan.
On a positive note, the price by volume chart shows a lot of buying in this range, which should hopefully provide support. First traget is to get out of this post earnings funk. We need to break 2.00 and get through resistance at 2.05-2.09, which corrsponds to the recent spike high, support lows in Feb, and the descending trendline. Hmm.... that sounds like quite a bit of work, but hopefully as more details are released about the launch, we should get some momo back/
Just my thoughts
It seems INSM is ready to go up
http://stockcharts.com/h-sc/ui?s=INSM&p=D&b=5&g=0&id=p18738740016.
(1) BB width is very narrow.
(2) MFI is still > 50%
(3) If not because of today market, we should stay above 200ema.
Some Ugly selling of INSM the last couple of days with the down market - not a lot of volume but no interested buyers to pick up the price. INSM broke down below my previously indicated support at 1.64-1.66, sitting around 1.61 for a lot of the day, but gained just enough to close above this support level at 1.66. Looking at the chart suggests that this level really should hold as support, but the small symmetrical triangle that it broke down from would put a target of around 1.30 in play, and additionally it is in the middle of a clear bearish price channel with a base currently of around 1.40. If the 1.59-1.66 support band it is playing with right now doesn't hold, INSM could very easily head down to test the channel support. Not a pretty sight :P
All seems a bit strange with the launch just around the corner. I for one am really hoping that this support level holds, as I think INSM is heavily undervalued here, and would be loath to sell at this price, knowing that higher prices surely must be ahead.
CURRENT INSM HIGHLIGHTS:
1) INSM launched commercially its FDA-Approved IPlex 4 weeks ahead of schedule.
2) Earnings for 2Q will likely exceed analysts' expectation by a wide margin due to the early iPlex commercial launch. During 2Q 2006, iPlex will be in the market for 6 weeks instead of the 2 weeks that analysts' had expected.
3) INSM has $60M in cash. These funds are sufficient to fund operations until mid-2007 excluding any iPlex revenues.
4) INSM will formally apply with the EMEA in a few weeks for iPLex approval in Europe. INSM has not ruled out a partnership with a large pharma Co. to market iPlex in Europe..
5) On June 13, a federal court dismissed a complaint filed by rival Tercica Inc. (Nasdaq: TRCA) claiming that INSM made false and misleading promotional statements related to its Iplex treatment for severe short stature in children.
***** CLINICAL DEVELOPMENT of INSM'S HUGE DRUG PIPELINE.
On May 15, 2006, a company representative addressing institutional investors clearly said that there will be many clinical trial results published within the next 6 months.
* NOONAN's syndrome trials. This is to expand iPlex patient base from 6,000 to over 30,000.
* Miotonic Muscular Disthrophy (MMD) clinical trials using iPlex are well under way.
Myotonic dystrophy affects an estimated 40,000 individuals in the United States.
* BP3 cancer trials....Ongoing (see ASCO news above)
BP3 has demonstrated preclinical efficacy in numerous cancer indications, including breast, prostate, liver, ovarian, and colon cancers.
* INSM-18 AT THE FOREFRONT OF NEW CANCER DRUGS....EVEN AHEAD OF PFIZER IN THIS AREA
On March 7, 2006, the Business Intelligence firm La Merie S.L. reported that antibodies are at the forefront of novel cancer therapeutics targeting the insulin-like growth factor-1 receptor (IGF-1R).
The report states that INSM along with giant Pfizer are among the leaders in this promising oncology research area. INSM-18 is a dual inhibitor of IGF-1R and Her2/neu and is the only clinical stage IGF-1R small molecule antagonist (phase I/II in prostate cancer).
http://www.pr.com/press-release/7579
ENDO 2006....On Tuesday, June 27, 2006, at this year's ENDO conference, INSM presented study results showing that Iplex is effective in increasing growth and improving glycemic control in patients with severe insulin-resistance syndromes, specifically Leprechaunism and Type A syndrome.
In another clinical trial, Iplex significantly improved height velocity in children with severe primary insulin growth factor-I deficiencies, the company said. Finally, a third study of the pharmacokinetics of Iplex in normal adults also showed positive results.
Iplex is already approved in the United States as a once-daily treatment for children with short stature associated with severe primary IGF-I deficiency.
http://biz.yahoo.com/bw/060622/20060622005174.html?.v=1
NOTE:
iPlex is a proprietary INSM drug product for the delivery of recombinant insulin-like growth factor 1 (IGF-1). It is administered as a preformed complex with a recombinant form of its natural binding protein, insulin-like growth factor binding protein 3 (rhIGFBP-3) or BP3.
BP3 helps regulate the distribution of IGF-1 and prevents IGF-1 excess. Uncontrolled IGF-1 has been linked to conditions as serious as accelerated cancer tumor cell growth.
DO YOUR DD
>:D
KEEP AN EYE ON INSM
Anyone else here speculating on INSM? After that sharp gain before mkt close yesterday, seems like something is happening behind the scenes. However, volume is low.
>:D...bOOOOHH!!....LOL
termabo,
I'm in at 1.75, and while I haven't much liked the recent action, I do agree with you that INSM should start moving higher in the coming weeks. Whatever happens with the lawsuit, as you said, it won't reach any real conclusion until Nov, what will really kick this off is the IPLEX launch and once analysts get an idea about IPLEX patient nos and potential revenues for the remainder o f2006 and 2007.
Recently I have decided to move more toward a long term hold phiilosophy as I'm getting a bit sick of the stresses involved in the swings of the market, as whenever I play to them, they always seem to spit me out. So for now, my 3 core holdings are INSM, NXXI, and GIGM. All of which I see as having huge potential in the next 12 months.
Don't want to put a price date target on these, but I do think that the next month or two should see things getting more interesting for INSM.
News of launch should make this thing skyrocket, Just rumors of launch and it takes off. conference call at earnings said in the next several weeks. So it could happen anytime.
MMs painting the for last squeeze before imminent rally. Keep an eye on this one.
INSM could be the buy of the year at these prices
Sometimes I wonder why i don't listen to my own advice but there you go - the day after my last post here, INSM gapped down hard and startyed playing in the 1.40s - really not nice, but I am determined to hang in on this one until the launch next month (which may or may not be a good idea, will only have to see). I'm not sure when it will rally but there should be one associated with the launch unless the market thinks IPLEX will bomb, but I don't think so.
So for now, I see some support around 1.45-1.46, and it would be nice for INSM to respect that. Changing my chart to a linear one, we have a descending wedge with a base currently around 1.35. I don't want it to test this once again, but if it does, I think I may have to load up there. Resistance at 1.65 seems to be causing some problems right now, but keep an eye out for the upside wedge breakout - I think that is when we will start to see some fireworks.
Its all inthe works guys.
Confirmed they have started majority of drug shipping today, rollout announcement
Confirmed they have started majority of drug shipping today, rollout announcement
One more day closer to a HUGE and PRITABLE JUNE.
We will enjoy June 'cause ;
Phase 2 clinical results Type A Extreme Insulin Resistance=results are very very encouraging said the Young ...--> end of june (27th) ;
IPlex's launch really soon (maximum end of June too...) ;
ASCOMeeting reallysoon...
....and i forget many things...
There's not volume right now..pps is low...but in my humble opinion : it's time to load before it skyrockets !
All that you have to know is there :
http://www.investorshub.com/boards/board.asp?board_id=1433
D.
INSM is forming a solid base....I expect the start of an uptrend any moment now....
There are many big investors on the sidelines ready to jump in at the sign of a clear reversal.
Once we go over $1.6 we'll start moving up....
HUGE June starts next week..
!!`Pfizer funds IGF-I/IGFBP-3 study !!
by: rigfbp3 (40/,)
Long-Term Sentiment: Strong Buy 05/24/06 08:30 am
Msg: 99097 of 99140
http://www.whri.qmul.ac.uk/staff/Savage.html
Martin Savage
Unit Head - Professor of Paediatric Endocrinology
Research Area:
Professor Martin Savage, Dr Cecilia Camacho-Hübner and Dr Linda Johnston hold academic positions in Paediatric Endocrinology. The principal interests of the unit are; the molecular and endocrine characterization of disorders of the GH-IGF-I axis, treatment of GH resistance with the recombinant IGF-I/IGFBP-3 complex, growth genetics and the investigation and treatment of paediatric Cushing's syndrome.
Clinical Activity:
There is close collaboration with Prof Adrian Clark's laboratory, where identification of several new mutations of the GH-IGF-I axis have been demonstrated. We are currently co-ordinating a pivotal therapeutic trial of the recombinant IGF-I-IGFBP-3 complex (Insmed Inc) in patients with GH insensitivity syndrome. The NESTEGG project (Network for the study of genes in growth) is directed by Adrian Clark and co-ordinated by Linda Johnston. This project, which unites populations of short stature patients from London, Rotterdam , Toulouse and Tübingen will study candidate genes for linkage of SNPs with phenotypic variants in idiopathic short stature and children born SGA. It is funded by Pfizer.
We currently have a database of 46 patients with paediatric Cushing's syndrome. Patients are referred from the UK, Europe and beyond. Characteristics of 30 patients with Cushing's disease have been recently published. We collaborate closely with the Department of Adult Endocrinology, Neurosurgery and Radiotherapy.
Recent publications:
* Pharmacokinetic studies of rhIGF-I/rhIGFBP-3 complex administered to patients with growth hormone insensitivity syndrome. Camacho-Hubner C, Rose S, Preece MA, Sleevi M, Storr HL, Miraki-Moud F, Minuto F, Frystyk J, Rogol A, Allan G, Sommer A, Savage MO.J Clin Endocrinol Metab. 2006 Jan 10
* Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 polymorphism in children. Sawczenko A, Azooz O, Paraszczuk J, Idestrom M, Croft NM, Savage MO, Ballinger AB, Sanderson IR. Proc Natl Acad Sci USA. 2005 Sep 13;102(37): 13260-5. Epub 2005 Sep 6.
* Joshi SM, Hewitt RJ, Storr HL, Rezajooi K, Ellamushi H, Grossman AB, Savage MO, Afshar F. Cushing's disease in children and adolescents: 20 years of experience in a single neurosurgical center. Neurosurgery, 57: 281-285.
* Storr HL, Afshar F, Matson M, Sabin I, Savage KM, Evanson J, Plowman PN, Besser GM, Monson JP, Grossman AB, Savage MO. Factors influencing cure by transsphenoidal selective treatment of pediatric Cushing's disease. European Journal of Endocrinology, 152: 825-833.
NESTEGG project: http://www.brightstudy.ac.uk/cgi-bin4/home_logos.cgi
RIG
Here we go ! ;) :D ;D
INSMED Announces IPLEX(TM) Availability
Here's the link :
http://www.shareholder.com/insmed/ReleaseDetail.cfm?ReleaseID=198504
Nice ;D ;D ;D
Lots rock!
INSMED BREAKOUT--> + 15% premarket ... :P
4 WEEKS AHEAD OF SCHEDULE!!!
HERE COME THE REVENUES, UPGRADES, AND BROADER ANALYST COVERAGE...
AND THE BIG ONE IS STILL AHEAD...THE JUNE 27 SEVERE INSULIN RESISTANCE PHASE 2 DATA PRESENTATION AT THE ENDO INTERNATIONAL CONFERENCE....
:-*
D.
Press Release Source: Insmed Incorporated
INSMED Announces IPLEX(TM) Availability Nationwide for Children with Severe Short Stature
Thursday May 25, 8:05 am ET
IPLEX Launch Marked By The First Product Shipments To Patients in States Across the Country
RICHMOND, Va.--(BUSINESS WIRE)--May 25, 2006--Insmed Incorporated (NASDAQ:INSM - News) announced today the nationwide availability of IPLEX(TM) (mecasermin rinfabate (rDNA origin). IPLEX was approved as an orphan drug by the Food and Drug Administration in December 2005 for the treatment of growth failure in children with severe primary IGF-I deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. IPLEX is the only once-daily IGF-I replacement therapy available for the treatment of severe primary IGFD.
"Insmed is very pleased to provide this novel therapeutic protein complex for the treatment of children who suffer from severe primary IGFD," said Philip J. Young, CBO. "It has been a 20-year journey for the many researchers involved in the development of IPLEX, and we are very gratified to finally have the opportunity to provide the only once-daily IGF-I therapy to patients in the United States. It is with great pleasure that we announce that on May 24, 2006 the first US patients with Primary IGFD began receiving IPLEX."
Primary IGFD is a distinct diagnosis of short stature and is believed to affect as many as 30,000 children in the United States. A subset of these patients is classified as having Severe Primary IGFD, which is estimated to affect 6,000 children. Severe Primary IGFD is a genetic or acquired condition in which patients do not generate sufficient quantities of IGF-I due to defects in the GH receptor/IGF-I pathway. In addition to the growth failure, Severe Primary IGFD can be associated with psychosocial problems. The early recognition and proper treatment of Severe Primary IGFD is critical in helping patients normalize growth and metabolic function.
"Numerous areas of the growth process remained a mystery for many years," said Mary Andrews, Executive Director of the MAGIC Foundation. "Now, thanks to the hard work of the researchers at Insmed, growth is better understood. It is so exciting to know that a new and convenient therapy is available for the many children with adequate levels of growth hormone who are not growing normally."
"As long time advocates for the diagnosis and treatment of children with growth issues, we recognize the importance of new and innovative approaches. We are pleased to welcome Insmed's debut into the field of pediatric growth therapy," adds Patricia D. Costa, Executive Director of the Human Growth Foundation.
IPLEX became available starting May 24 through a nationwide distribution system called PlexPoint(TM). PlexPoint is a single point of contact system for patients, payers and healthcare providers. PlexPoint can be accessed by calling 866-GO-IPLEX (866-464-7539) or on the web at www.go-IPLEX.com. The PlexPoint system is designed to provide the highest level of customer service to all stakeholders in the therapeutic decision-making and treatment processes. This system has been designed to provide flexibility and support to the payers, physicians, distributors and patients by allowing them to customize the distribution process to meet their individual needs.
More About IPLEX
Much of the data to support the FDA's approval last December were recently presented at the Pediatric Academic Societies' (PAS) 2006 Annual Meeting in San Francisco, California. At 12 months the ongoing study demonstrated significant, dose-dependent increases in growth rate. The investigators reported that the mean height velocity for the dose group titrated with up to 2 mg/kg/day increased from 2.0 cm/year pre-treatment to 8.3 cm/year during treatment. Children with genetic and acquired forms of GH insensitivity or IGFD appeared to respond equally well to treatment.
The once-daily dosing regimen used in the study was associated with a high compliance rate of 95% of injections taken. The safety profile of IPLEX proved favorable as instances of low blood sugar (hypoglycemia) were mostly mild and asymptomatic. Patients with severe GH insensitivity have a predisposition to hypoglycemia without treatment. Of the subjects enrolled in the study, 28% reported a history of hypoglycemia prior to treatment. This was similar to the proportion of subjects (31%) who experienced at least one incidence of hypoglycemia during the first year of treatment with IPLEX.
In the study, no patients discontinued IPLEX due to a related adverse event. Two patients had papilledema (one with a blocked pre-existing ventriculo-peritoneal shunt and one asymptomatic). No instances of facial nerve paralysis were reported. As is common with protein therapeutics, antibodies to the protein complex were detected in most patients, but were not associated with growth attenuation or adverse effects.
IPLEX is also being investigated for various other indications with unmet medical needs, including extreme insulin resistance, myotonic muscular dystrophy and HIV Associated Adipose Redistribution Syndrome (HARS) and short stature in children with Primary IGFD associated with Noonan Syndrome.
About Insmed Incorporated
Insmed is a biopharmaceutical company focused on the development and commercialization of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, log onto www.insmed.com or call 866-GO-IPLEX (866-464-7539) toll free.
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our regulatory and business strategies, plans and objectives of management and growth opportunities for IPLEX and other proposed products and our planned clinical trial design, . Such forward-looking statements are subject to numerous risks and uncertainties, including risks that IPLEX may not be successfully marketed or manufactured, competing products for IPLEX and our other proposed products may be more successful, our other product candidates may fail in the clinic or, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of our studies differently than we have, and the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in our filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to our reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and Insmed disclaims any intention or responsibility for updating predictions or financial guidance contained in this release.
Contact:
Insmed Incorporated
Natalie Wyeth, Media, 202-835-9473;
[email protected] or
Tim Ryan, Investors, 212-477-9007 ext. 24;
[email protected]--------------------------------------------------------------------------------
Source: Insmed Incorporated
With technicals gradually improving and several catalysts in sight for the next few weeks, INSM should continue to move up from here on up.
Good luck
FOOD FOR THOUGHT...
The early iplex launch has not been very good for the stock initially....but it will prove to be great for investors willing to hold for a few weeks...a couple of months the most to bet their best return.
The early commercial launch of INSM's FDA-approved iPlex did not increase the PPS as expected because the launch was done while the technicals were very weak. However, the benefits of such action will reward patient investors in a matter of just a few weeks.
INSM's results will exceed Wall Street expectations for 2Q 2006 by a wide margin. This is because iNSM will realize iPlex revenues for 6 weeks instead of the forecasted 2 week revenue for the quarter based on the guidance given by the company that IPlex would be launched in late June. This is the complete opposite of the results that rival TRCA posted last month (below the minimum consensus estimates).
Big investors already know that and that's why they are milking the last remnants of weak hands.
When will ISNM go up for good??.....This week without a doubt. As soon as an uptrend has been defined. That trigger price for the steady rally will be about $1.8...
HMMMM....NICE VOLUME AND PRICE SURGE ALL OF A SUDDEN... >:D
WEAK MARKET AND STRONG INSM.....TREND SHOULD CONTINUE THROUGH JUNE/JULY. ANOTHER BIOTEC WITH SHORT-TERM UPSIDE IS PPHM. THE ASCO SHOW CONFERENCE WILL HELP BOTH COMPANIES
I expect INSM to continue its slow and steadily climb to $2. After it goes above $2, it should move faster.
Philip J. Young, Executive Vice President of Commercial Operations and Chief Business Officer spoke to institutional investors on May 15, 2006 at Rodman & Renshaw 3rd Annual Global Healthcare Conference:
http://www.insmed.com/updates/second...ebcasts§ion=ir
Great confident presentation.
Mr. Young said in the mid-May presentation they INSM was planning on launching iPlex in a few weeks.....and less than 2 weeks later they did just that!!!! Simply amazing.
He also said that the people they hired are top notch....people he knew at Genetech and Pharmacia. I believe he used to work for DNA.
The most amazing thing is that INSM was able to assemble its superb sales, marketing, clinical, and manufacturing team in just a few months with top notch people. The things that impressed me the most about the personnel they hired is:
-- 17 years average experience !!
-- These people have participated in 29 new product launches !!
-- 80% of the new people have more than 10 years experience calling on Pediatric Endochrinologists!!
So now INSM has the best team and the best product.....and it already shows it. They launched iPlex 6 weeks ahead of their original target.
Mr. Young also gave an update on the clinical development of the hudge drug pipeline. He could not contain his enthusiasm when he talked about the upcoming Severe Insulin Resistance podium presentation at this month's ENDO Conference...
There is a bunch of clinical data that will be presented this year from a series of clinical trials.
--- Muscular Dystrophy
--- Noonan's Syndrome
--- INSM- 18 refractory cancer
--- pb3 prostate cancer
--- Several other iPLex indications
Terabemo:
Honestly suggest you accompany PRs with some substantial TA because
please note you have accumulated so many smittes that perhaps some people
are not happy with your method of cheering this stock.
Just an opinion
jorgegr
INSM NEWS TODAY...
http://biz.yahoo.com/bw/060609/20060609005083.html?.v=1
BIGGEST JUNE EVENT WILL BE THE FORMAL RELEASE OF PHASE 2 SEVERE INSULIN RESISTANCE CLINICAL DATA (IPLEX)AT THE ENDO CONFERENCE ON JUNE 27
COMPANY SAIS REPETEADLY THAT THE DATA IS...."COMPELLING"....AND THAT INSM WILL BE A PLAYER IN THIS MULTI-BILLION $$$$ MARKET
Hello...
here's a little progress...
http://finance.yahoo.com/q?s=INSM&d=t
Court Dismisses Baseless Unfair Business Practices Lawsuit That Was Brought Against Insmed +
Court dismisses Tercica complaint against Insmed
INSM will present "COMPELLING DATA" for phase 2 clinical results using iPlex to decrease Severe Insulin Resistance. Presentation will be made in 3 weeks at the ENDO international Show/Conference
One day closer to hitting the jackpot....
JUNE 27...."COMPELLING DATA"....ACCORDING TO INSM CEO, ON PHASE 2 IPLEX CLINICAL TRIALS ADDRESSING SEVERE INSULIN RESISTANCE......A MULTI-BILLION DOLLAR MARKET
terrible market in general....call me crazy, but I am buying INSM and RDCM with both hands literally at these prices.
good luck to all
Looking good so far...
Quote from: terabemo on June 14, 2006, 09:42:47 AM
Looking good so far...
hhmmm,
down a penny , looking strong quick everybody get in you'll miss the boat, oh no you don't want to miss this baby going to the moon, how will you sleep at night., ;D
terrabeemo, just copy and paste this post so you won't have to type ;D
maxi
Hey guys
50MA at 1.68 crossed down 200MA
CCI(20) at 171.20 RSI (14) at 30.6 MACD (12,26,9) at -0.08 downward
Price relative to SPY 0.0111 EMA (20) 0.0123 downward
Today's price at 1PM = 1.38 three cents lower than yesterday's close
Hope somebody can find a good therapy for this one because so far seems to be deaf
to prayers :'(
jorgegr
HUGE INSM DIABETES NEWS JUST A FEW DAYS AHEAD....
INSM MOVING UP!!
On June 25, INSM will present "COMPELLING DATA," according to a company official, for phase 2 clinical results using iPlex to decrease Severe Insulin Resistance.
This will be a podium presentation at this year's ENDO international Show/Conference. The same company official claimed at a recent investor's conference that "INSM expects to be a PLAYER" in this multi-billion dollar market.
I expect 50c/share++ gain and more than 10M shares traded after the PR for the above event is released
Looks like we are going to have some buyers during the last trading hour.
CALL ME CRAZY....BUT I AM ADDING INSM AT $1.35 WITH BOTH HANDS....
NEXT WEEK IS THE LAST WEEK BEFORE THE BIG INTERNATIONAL ENDO CONFERENCE WHERE INSM WILL PRESENT SIGNICANT TRIAL RESULTS FOR SECERE INSULIN RESISTANCE
Quote from: terabemo on June 16, 2006, 03:10:56 PM
CALL ME CRAZY....BUT I AM ADDING INSM AT $1.35 WITH BOTH HANDS....
alright, you're crazy!
maxi :D
INSM should start moving up ahead of next week's ENDO conference.
INSM will present "compelling results" of Phase 2 clinical trials to treat Severe Insulin Resistance is hard-to-treat diabetes patients on June 27.
Once INSM crosses $1.5 it should run like a wild bronco.
BREAKOUT??..
IT SURE LOOKS LIKE IT.....
Looking for a nice close.
Today might be the last day to buy in the low $1.40's.
Newly added INSM presentation at ENDO 2006....this new iPlex application is in addition to Severe Insulin Resistance Phase 2 results to be reported June 27, 2006. Next week could be HUGE for INSM.
[P2-678] Divergent Effects of the IGF-I/IGFBP-3 Complex over GH and Ghrelin Nocturnal Concentrations in Small for Gestational Age Children.
German F Iniguez, Teresa E Salazar, Rossana Roman, Alejandra Avila, Ronald D Gunn, Fernando Cassorla, Inst of Matern and Child Res, Sch of Med, Univ of Chile, Santiago, Chile; INSMED, Glen Allen, VA
The complex interplay between GH, IGF-I and Ghrelin has not been clearly established in humans. In particular, it is not known whether IGF-I regulates circulating ghrelin concentrations, either directly, or through its effect on GH. In order to determine the effects of IGF-I over GH and ghrelin concentrations, we examined the GH and ghrelin nocturnal profiles before and after the administration of the IGF-I/-IGFBP-3 complex (IPLEX) in small for gestational age children.
Twenty small for gestational age, prepubertal children (11 boys and 9 girls), born after a full-term pregnancy were studied at a mean age of 7.3+0.5 years (range 4 to 11 years). Their mean height was -1.8+0.3 SDS and their mean BMI was 0.1+0.2 SDS at the time of the study. The children were studied twice, the first time under basal conditions, and the second time, 2 to 4 weeks later, after the sc administration of 1 mg/kg of IPLEX at 9PM. Blood samples for determination of GH and Ghrelin were obtained every 20 min between 11PM and 7AM, while the children were sleeping . Full length octanoylated human ghrelin was measured with a commercial RIA kit from Linco, and GH was measured with a double antibody RIA.
In each patient, we determined serum IGF-I and IGFBP-3, and calculated the mean GH and Ghrelin area under the curve (GH AUC and GHR AUC), both under basal conditions and after the administration of IPLEX. Results are shown in the Table as mean SEM.
As shown in the Table 1, serum IGF-I and to a lesser extent serum IGFBP-3, increased significantly after IPLEX administration.
In addition, mean nocturnal GH AUC exhibited a significant decrease after IPLEX, whereas mean GHR AUC showed a significant increase after administration of the IGF-I/IGFBP-3 complex.
We did not observe any differences in the response to IPLEX according to gender.
These findings indicate that the IGF-I/IGFBP-3 complex appears to have opposite effects over circulating GH and Ghrelin concentrations in small for gestational age children, suggesting that in addition to its known negative feed-back effect over GH, IGF-I may have a positive feed back effect over Ghrelin.
http://www.abstracts2view.com/endo/search.php?search=do&intMaxHits=10&where%5B%5D=&andornot%5B%5D=&query=insmed
Published research in May indicate the importance of Ghrelin:
Ghrelin: A player in diabetes but not obesity?
10.05.2006
Ghrelin, a hormone long considered a key player in obesity, may instead take a major role in maintaining the balance between insulin and glucose and the development of diabetes, said Baylor College of Medicine researchers in a report in the current issue of the journal Cell Metabolism.
"Everybody has been pushing the connection between obesity and ghrelin," said Dr. Roy G. Smith, director of the BCM Huffington Center on Aging, "Companies have been developing ghrelin antagonists as anti-obesity drugs. Now these drugs may have a value in treating diabetes."
http://www.innovations-report.com/html/reports/medicine_health/report-58893.html
Scf
The reversal that is starting to take shape (see chart) is primarily because of the anticipation about the two INSM presentations (1 and 2 below) at this week's The Endocrine Society's 88th Annual Meeting (ENDO 2006) to be held in Boston from June 24 - June 27.1) On June 27, INSM will present "COMPELLING DATA," according to a company official, for phase 2 clinical results using iPlex to decrease Severe Insulin Resistance.
This will be a podium presentation at this year's ENDO international Show/Conference.
The same company official claimed at a recent investor's conference that "INSM expects to be a PLAYER" in this multi-billion dollar market.
I expect a significant pps gain on huge trading volume after the PR for the above event is released
2) A new INSM presentation has just been added to this year's ENDO conference schedule. The study deals with the effects of the IGF-I/IGFBP-3 Complex (iPlex) over Growth H and Ghrelin Nocturnal Concentrations in Small for Gestational Age Children. Ghrelin, a hormone long considered a key player in obesity, may instead take a major role in maintaining the balance between insulin and glucose and the development of diabetes, said Baylor College of Medicine researchers in a report in the current issue of the journal Cell Metabolism. 3) On June 13, a federal court dismissed a complaint filed by rival Tercica Inc. (Nasdaq: TRCA) claiming that INSM made false and misleading promotional statements related to its Iplex treatment for severe short stature in children.
4) FDA-Approved IPlex Commercial Launch ----- DONE...4 weeks ahead of schedule. iPlex is a proprietary INSM drug product for the delivery of recombinant insulin-like growth factor 1 (IGF-1). It is administered as a preformed complex with a recombinant form of its natural binding protein, insulin-like growth factor binding protein 3 (rhIGFBP-3) or BP3. BP3 helps regulate the distribution of IGF-1 and prevents IGF-1 excess. Uncontrolled IGF-1 has been linked to conditions as serious as accelerated cancer tumor cell growth.
5) INSM has $60M in cash. These funds are sufficient to fund operations until mid-2007 excluding any iPlex revenues
6) Earnings for 2Q will exceed analysts' expectation by a wide margin because of 1 above.
7) Surveys by analysts indicate that IPlex is preferred by pediatric doctors for safety reasons and once/daily dosage.
8) INSM will formally apply with the EMEA in a few weeks for iPLex approval in Europe. INSM has not ruled out a partnership with a large pharma Co. to market iPlex in Europe..
9)ASCO published this week a milestone paper describing the relationship between PB3 and cancer prevention/cure. Essentially PB3 neutralizes excess IGF-1 (Increlex) which if allowed to exist unbuffered could fuel uncontrolled cell growth including tumors/cancer.
http://www.asco.org/portal/site/ASCO/menuitem.d773f70619f767fd506fe310ee37a01d/?vgnextoid=4cca201eb61a7010VgnVCM100000ed730ad1RCRD&reuterview=detail_view&reutersid=4868
10) CLINICAL DEVELOPMENT of INSM'S HUGE DRUG PIPELINE. On May 15, 2006, a company representative addressing institutional investors clearly said that there will be many clinical trial results published within the next 6 months.
* NOONAN's syndrome trials. This is to expand iPlex patient base from 6,000 to over 30,000.
* Miotonic Muscular Disthrophy (MMD) clinical trials using iPlex are well under way.
Myotonic dystrophy affects an estimated 40,000 individuals in the United States.
* BP3 cancer trials....Ongoing (see ASCO news above)
The company's product candidate (BP3), rhIGFBP-3, recombinant human Insulin-like Growth Factor Binding Protein-3, is a naturally occurring anti-tumor agent. rhIGFBP-3 has demonstrated preclinical efficacy in numerous cancer indications, including breast, prostate, liver, ovarian, and colon cancers.
* INSM-18 AT THE FOREFRONT OF NEW CANCER DRUGS....EVEN AHEAD OF PFYZER IN THIS AREA
On March 7, 2006, the Business Intelligence firm La Merie S.L. reported that antibodies are at the forefront of novel cancer therapeutics targeting the insulin-like growth factor-1 receptor (IGF-1R).
The report states that INSM along with giant Pfizer are among the leaders in this promising oncology research area. INSM-18 is a dual inhibitor of IGF-1R and Her2/neu and is the only clinical stage IGF-1R small molecule antagonist (phase I/II in prostate cancer).
http://www.pr.com/press-release/7579
DO YOUR DD
Quote
>:D
INSM is dusting off its rally clothes....looks ready to start moving up.
The ENDO news in the next few days could make it jump past $2. Even then, it would still be one of the most undervalued biotec stocks in the market.
I am looking to buy one of these 3 stocks. After much research I am still not sure which is the one. All 3 seem to have great things going. Anyone have any suggestions? Are you holding these? What are your thoughts?
INSM BREAKING OUT!!!!
COULD GO OVER $2 EASILY AFTER THE ENDO PRESENTATIONS LATE THIS WEEK AND MONDAY
please check the FRPT Subject & Analysis via Search Functionality 8)
cheers
Oliver
>:D
Fundamentals and Technicals are coming together at the right time.
TA traders will like the chart and will start joining in the buying frenzy that is about to get started.
Guys...
News out :
Read it... ( and happy to know that Iplex could BE used in several sides )
Insmed Endocrine Society 2006 Update
Thursday June 22, 8:04 am ET
Insmed Will Report Efficacy of IPLEX(TM) in Patients with Severe Insulin Resistance
Company Also to Present Data on the Unique Pharmacokinetics of IPLEX
RICHMOND, Va.--(BUSINESS WIRE)--June 22, 2006--Insmed, Inc (NASDAQ: INSM - News) today announced that investigators from the University of Cambridge, UK, will be presenting new results on the safety and efficacy of its insulin-like growth factor drug, IPLEX(TM) (mecasermin rinfabate (rDNA origin) injection), in patients with severe insulin resistance syndromes at the annual meeting of the Endocrine Society in Boston, MA. This platform presentation will be given on Tuesday, June 27 at 11:30 a.m., Room 206 of the Boston Convention and Exhibit Center. The title of the talk is:
rhIGF-1/rhIGFBP-3 Treatment of Patients with Severe Insulin Resistance Syndromes: Preliminary Data, Fiona Regan, Marc de Kerdanet, Mehul Dattani, Andreas Sommer, Kenneth M Attie, David B Dunger. (ENDO Abstract OR40-2)
Insmed also will be presenting additional data demonstrating the safety and efficacy of IPLEX on patients with severe IGF-I deficiency. In addition, two posters will highlight the attributes of IPLEX's pharmacokinetic profile. Studies to be presented include:
Once Daily rhIGF-1/rhIGFBP-3 Treatment Improves Growth in Children with Severe Primary IGF-I Deficiency: Results of a Multicenter Clinical Trial (ENDO Abstract OR40-1, Tuesday, June 27, 11:15 a.m., room 206, Boston Convention and Exhibit Center)
Subcutaneous Administration of rhIGF-1/rhIGFBP-3 in Healthy Adult Volunteers Does Not Result in Supraphysiological Concentrations of Free IGF-I (ENDO Abstract P1-192, Saturday June 24, 11 a.m., poster session, Boston Convention and Exhibit Center)
Pharmacokinetics of Single Dose Subcutaneous Administration of rhIGF-1/rhIGFBP-3 in Healthy Adult Volunteers (ENDO Abstract P1-191, Saturday, June 24, 11 a.m., poster session, Boston Convention and Exhibit Center)
"We are extremely pleased to be presenting data at two poster and two podium presentations. We believe that IPLEX is a breakthrough drug that is showing very promising results in patients with severe insulin resistance. The preliminary data that will be presented at ENDO 2006 show that IPLEX may be beneficial for treating these patients, who are generally unresponsive to conventional therapies," remarked Kenneth M. Attie, M.D., Vice President, Medical Affairs, Insmed. "Additional data being presented supports the rationale for developing a unique dual protein therapeutic to closely mimic normal human physiology."
IPLEX is approved in the United States for the treatment of growth failure in children with severe primary IGF-I deficiency (Primary IGFD).
cheers
D. :)
INSM ROCKS!!! >:D
This time you are in track.
After yesterday's white candle breakout from the falling
trend, could be a reversal and shorts covering will help.
Good luck to those holding.
jorgegr
Buying on the dips.... >:D
Chart looks MUCH BETTER! ;D
We could have a nice rally this afternoon. I wouldn't be surprised to see $1.7 - $1.8 today.
Good luck
INFORMATION :
SIR podium pres. monday @ 11:30AM
by: l_oompa (40/,)
Long-Term Sentiment: Strong Buy 06/23/06 09:01 am
Msg: 109724 of 109724
...and 2 poster sessions in the weekend. Not too much time left to buy some cheap shares.
Off-label implications for using IPLEX for athletes and adults and SIR phII results & "the rationale for developing a unique dual protein therapeutic" for T1DM, will make this stock soar.
time to load ....
D.
I agree 100%
I guessed correctly this time. It closed at $1.73.
Next week will be interesting..... ;D
good luck, TA is positive IMO
Good luck to all holding INSM. This week will be interesting.
THe ENDO news should come out Monday afternoon or Tuesday because they can't do it until after the presentation. The big one is at 11:30AM. There will be a buying opportunity early tomorrow....but that's it.
INFORMATIONS2 more upgrades... ;D
FORBES:
http://tinyurl.com/g557g
BIOSPACE:
Insmed Incorporated
4851 Lakebrook Drive
Glen Allen, Virginia 23060 U.S.A.
Phone: 804-565-3000 Fax: 804-565-3500
E-Mail:
[email protected] Mini-Profile
News
Insmed Incorporated News from The BioSpace Beat
Join the BioSpace Directory of BioScience Companies
See What Your Profile Could Look Like!
Upgrade Insmed Incorporatedto a BioSpace standard profile BUY NOW!
Request More Information
http://tinyurl.com/gg3a4
PLEASE NOTICE THE NEW MAILADRESS!!
[email protected]!!!!!!!
Sofar analysts updates; both valid as of 6/26/06
AND don't forget :
A man called Ivalexy made a good summary :
http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=1600811390&tid=insm&sid=1600811390&mid=110269
Pfffff, and blablablablablaaaaaaaaaaaaa;
one last thing :
INSM is included in the Russell Microcap index:
http://www.russell.com/US/Indexes/US/membership.asp
Page 9.
D.
;)
the chart.......
Stalemate....waiting for the news...the news will be good...:)
Setravis, INSM looking good, we need more volume, I think it's coming ;) :D ;D
short update:
INSM: Short Interest UP 53.7% to 2.7M in Jun 2006
Monday , June 26, 2006 16:18 ET
According to new short interest data from NASDAQ, short interest for Insmed Incorporated (NasdaqNM: INSM) INCREASED 53.7% to 2,684,506 shares for the month ended mid-June, 2006.
SYMBOL MAY JUNE CHANGE %CHANGE DAYS/COVER
-------- ------------- ------------- ------------- ------------ ----------
INSM 1,747,125 2,684,506 +937,381 +53.65% 4
Based on INSM's 20-day average daily share volume of 798,140, it would require approximately 4 day(s) of buying to cover this short interest.
"Very positive and compelling presentation...."
This platform presentation will be given on Tuesday, June 27 at 11:30 a.m., Room 206 of the Boston Convention and Exhibit Center. The title of the talk is:
rhIGF-1/rhIGFBP-3 Treatment of Patients with Severe Insulin Resistance Syndromes: Preliminary Data, Fiona Regan, Marc de Kerdanet, Mehul Dattani, Andreas Sommer, Kenneth M Attie, David B Dunger. (ENDO Abstract OR40-2)
Insmed also will be presenting additional data demonstrating the safety and efficacy of IPLEX on patients with severe IGF-I deficiency. In addition, two posters will highlight the attributes of IPLEX's pharmacokinetic profile. Studies to be presented include:
Once Daily rhIGF-1/rhIGFBP-3 Treatment Improves Growth in Children with Severe Primary IGF-I Deficiency: Results of a Multicenter Clinical Trial (ENDO Abstract OR40-1, Tuesday, June 27, 11:15 a.m., room 206, Boston Convention and Exhibit Center)
Subcutaneous Administration of rhIGF-1/rhIGFBP-3 in Healthy Adult Volunteers Does Not Result in Supraphysiological Concentrations of Free IGF-I (ENDO Abstract P1-192, Saturday June 24, 11 a.m., poster session, Boston Convention and Exhibit Center)
Pharmacokinetics of Single Dose Subcutaneous Administration of rhIGF-1/rhIGFBP-3 in Healthy Adult Volunteers (ENDO Abstract P1-191, Saturday, June 24, 11 a.m., poster session, Boston Convention and Exhibit Center)
"We are extremely pleased to be presenting data at two poster and two podium presentations. We believe that IPLEX is a breakthrough drug that is showing very promising results in patients with severe insulin resistance. The preliminary data that will be presented at ENDO 2006 show that IPLEX may be beneficial for treating these patients, who are generally unresponsive to conventional therapies," remarked Kenneth M. Attie, M.D., Vice President, Medical Affairs, Insmed. "Additional data being presented supports the rationale for developing a unique dual protein therapeutic to closely mimic normal human physiology."
D.
ps: for me...news after hours....
QuoteInsmed Presents Positive IPLEX(TM) Data At ENDO 2006
Tuesday June 27, 11:30 am ET
BOSTON--(BUSINESS WIRE)--June 27, 2006--Insmed, Inc. (NASDAQ: INSM - News):
Results from 3 IPLEX studies demonstrate:
* IPLEX increases growth and improves blood sugar control in patients with severe insulin-resistance syndromes, such as Leprechaunism and Type A syndrome (1)
* IPLEX improves growth rate in children with severe primary IGF-I deficiency(2)
* IPLEX safely increases IGF-I levels in healthy adults without causing abnormal increases in free IGF-I levels.(3)
Insmed, Inc. (NASDAQ: INSM - News) today announced new study results that show that IPLEX(TM) (mecasermin rinfabate (rDNA origin) injection) is effective in increasing growth and improving glycemic control in patients with severe insulin-resistance syndromes, specifically Leprechaunism and Type A syndrome. In another clinical trial, once-daily treatment with IPLEX significantly improved height velocity in children with severe primary insulin growth factor-I (IGF-I) deficiencies. A third study of the pharmacokinetics of IPLEX in normal adults showed positive results, with simultaneous increases in IGF-I and IGFBP-3 and without undue increases in "free" IGF-I. Findings of all three studies were presented this week at the annual meeting of the Endocrine Society, ENDO 2006.
In a study showing the impact of IPLEX treatment on infants diagnosed with Leprechaunism (or Donohue syndrome) (Abstract OR40-2), preliminary results indicate IPLEX improved growth and glycemic (glucose) control, as well as potentially prolonged the life of at least one patient. Leprechaunism, the rarest and most severe insulin resistance syndrome, is diagnosed in infancy and in some patients can result in death in the first year of life. In this study, two patients with Leprechaunism were treated with IPLEX. Results showed an improved height standard deviation score in both patients (one from -3.3 pre-treatment to -2.4 with treatment and the second from -2.8 pre-treatment to -1.8 with treatment). Additionally the first patient achieved a reduction in HbA1c (7.6 percent pre-treatment to 6.7 percent with treatment), as well as a decrease in mean daily glucose levels (9.4 mmol/L pre-treatment to 6.6 mmol/L with treatment), indicating IPLEX produced a significant physiological benefit in this patient. This patient has been on therapy for three years and both patients currently remain on IPLEX treatment.
In the severe insulin resistance study, three adolescents with Type A syndrome, a disease in which the patient exhibits poor glycemic control despite conventional therapies, were evaluated on IPLEX treatment. Each patient entered the trial with elevated glucose levels and inadequate response to treatment with traditional therapeutic agents. Results showed that these patients, when treated with IPLEX, demonstrated approximately a 20% average decrease in HbA1c and daily glucose levels. Patients receiving IPLEX experienced decreased glucose excursions, reduced insulin usage, and noticed less prominent acanthosis nigricans (dark, velvety skin patches), which are commonly associated with severe insulin resistance. In further evidence of drug-dependent changes, all of these improvements worsened in each patient once IPLEX treatment was terminated.
"The preliminary results of this study suggest that IPLEX can be more effective than conventional diabetes therapies in patients with severe insulin resistance syndromes," said Kenneth M. Attie, M.D., Vice President, Medical Affairs, Insmed. "We look forward to the completion of these studies with IPLEX and continuing to evaluate its utility in diabetes-related disorders, particularly in those with extreme insulin resistance."
Safety and Efficacy in Children with Severe Primary IGF-I Deficiency
A second study (Abstract OR 40-1) presented at ENDO demonstrates IPLEX's safety and efficacy in children with severe primary IGF-I deficiency. A prospective, multicenter clinical trial of IPLEX administered once daily showed that treatment resulted in statistically significant, dose-dependent increases in height velocity (growth rate) with a favorable safety profile. Average height velocity in one of the treatment groups, treated with a dose of up to 2 mg/kg/day, increased from 2.0 cm/year pre-treatment to 8.3 cm/year during the first year of treatment. Children with genetic and acquired forms of growth hormone (GH) insensitivity appeared to respond equally well to treatment in this study.
IPLEX was generally well tolerated in these patients. Adverse events included injection site reactions (including erythema, lipohypertropy, and hair growth), hypoglycemia (generally rated as mild and asymptomatic), headache, and tonsillar/adenoid hypertrophy.
IPLEX Pharmacokinetics in Normal Adults Presented
Results from a pharmacokinetic study of IPLEX, presented during 2 poster presentations, demonstrate that IPLEX has unique, positive properties. The first poster (P1-191) presented the pharmacokinetic results of single-dose administration of the drug to 28 healthy adult volunteers. The investigators concluded that due to the gradual absorption and elimination of IPLEX in the bloodstream, sustained increases in levels of IGF-I and IGFBP-3 are achieved lasting more than 24 hours. These data indicate that the drug can be administered once-daily or, in certain patient populations, possibly less frequently, such as every other day. IPLEX was well tolerated during the study.
A second poster from this study (P1-192) examined the levels of free IGF-I in healthy adult volunteers after administration of IPLEX. Under normal circumstances, less than 2 percent of IGF-I circulates as the free biologically active form because of a complex physiology that keeps it bound to other proteins, principally IGFBP-3 and ALS. The IPLEX complex was designed to limit the amount of free IGF-I associated with replacement therapy, thus maintaining a physiological balance of IGF-I with IGFBP-3. Results of this study conclude the mean percent of free IGF-I did not exceed 1 percent at any time during the 72-hour sampling period, thus avoiding supra-physiologic levels of free IGF-I.
"IPLEX was designed to provide IGF-I in a stable complex with its natural binding protein, and thus mimic what occurs naturally in human circulation," said Attie. "In the pharmacokinetic study presented at ENDO, we demonstrated that the drug limits the excursions of free IGF-I levels by providing a gradual absorption of the apparently intact complex. The pharmacokinetics of this drug make it an ideal treatment for children with severe primary IGFD and, in the future, other patient populations that might benefit from once daily IGF-I replacement."
About IPLEX
IPLEX is approved in the United States as the only once daily treatment for children with short stature associated with severe primary IGF-I deficiency (Primary IGFD). IPLEX, a complex of recombinant human IGF-I and its binding protein IGFBP-3 (rhIGF-I/rhIGFBP-3), is the only FDA-approved IGF-I replacement therapy that also replaces deficient IGFBP-3 in these patients. The drug, which was launched in the second quarter of 2006, is also being investigated for various other indications with unmet medical needs, including severe insulin resistance, myotonic muscular dystrophy and HIV Associated Adipose Redistribution Syndrome (HARS). For more information about IPLEX please go to www.go-IPLEX.com.
::)
so what to understand with that ?!
on good news...they fall !!
sell order active
fake breakout ??? ???
feedback is appreciated
O.
Insmed dips after weeklong rally
Tuesday , June 27, 2006 15:14 ET
By Staff Reporter
BOSTON, Jun 28, 2006 (XFN-ASIA via COMTEX) -- Shares of Insmed Inc. dipped Tuesday following a weeklong climb after the biotech drug maker released results from clinical trials testing its Iplex growth factor treatment.
Insmed fell 12 cents, or 7 percent, to $1.67 in afternoon trading on the Nasdaq at above average volume. Before the release of data, shares had risen 23 percent from last Tuesday's close of $1.46. Shares have traded between 86 cents and $3.35 over the past 52 weeks.
In one study, the company said Iplex improved height deviation scores and blood sugar levels of two patients with Donohue syndrome, the most severe form of insulin resistance that can result in death. Also known as "Leprechaunism," the rare condition is often diagnosed in infancy and results in short stature and elfin-like features.
Using Iplex for another insulin resistance disease called Type A syndrome, three adolescents were shown to have their blood sugar levels reduced by an average 20 percent. Insulin is the hormone that allows the body to regulate blood sugar.
Another study showed that growth spurts in children increased by an average of about 3.3 inches from about 0.8 inches per year in the first year of treatment in children with severe insulin growth factor-I deficiencies.
A safety study following 28 adults showed that insulin growth factor levels were increased for 24-hour periods after taking Iplex, and that the drug was well tolerated.
The most frustrating stock in America will have its day in the sun. Very soon IMO.....I am long on this one.....50%++ is earmarked for 3-year hold. Nice retirement account IMO
I-Watch suggests that most of the buying after the ENDO conference has been institutional. I like that... :)
INSM $1.6
INSM's July rally factor will be 2Q 2006 earnings. I expect earnings to exceed analysts' expectations. Analysts expected 2 weeks of iPlex revenues but the company launched iPlex 4 weeks ahead of schedule. Most of the buys on Friday were at the ask with a 10K share buy the last second of trading ...and 3 cents above the ask.
http://stockcharts.com/gallery/?insm
RDCM: $2.24
RDCM has 80c/share cash no debt and strong guidance for earnings to be reported during the 3rd week of July. If the company meets guidance we could see $4+ after earnings. Interestingly, one of the last trades on Friday was for 32000 shares at the ask $2.24. I believe that RDCM will start moving up on today.
http://stockcharts.com/gallery/?rdcm
EVOL: $1.26
EVOL is superundervalued. If earnings are even slightly encouraging, EVOL will fly past $2 in NY second.
http://stockcharts.com/gallery/?evol
DO YOUR DD
1 and 2 below will be catalysts for INSM's July rally:
1) Earnings for 2Q will likely exceed analysts' expectation by a wide margin due to the early iPlex commercial launch. During 2Q 2006, iPlex will be in the market for 6 weeks instead of the 2 weeks that analysts' had expected.
2) INSM will formally apply with the EMEA in a few weeks for iPLex approval in Europe. INSM has not ruled out a partnership with a large pharma Co. to market iPlex in Europe..
3) INSM has $60M in cash. These funds are sufficient to fund operations until mid-2007 excluding any iPlex revenues.
4) On June 13, a federal court dismissed a complaint filed by rival Tercica Inc. (Nasdaq: TRCA) claiming that INSM made false and misleading promotional statements related to its Iplex treatment for severe short stature in children.
***** CLINICAL DEVELOPMENT of INSM'S HUGE DRUG PIPELINE.
On May 15, 2006, a company representative addressing institutional investors clearly said that there will be many clinical trial results published within the next 6 months.
* NOONAN's syndrome trials. This is to expand iPlex patient base from 6,000 to over 30,000.
* Miotonic Muscular Disthrophy (MMD) clinical trials using iPlex are well under way.
Myotonic dystrophy affects an estimated 40,000 individuals in the United States.
* BP3 cancer trials....Ongoing (see ASCO news above)
BP3 has demonstrated preclinical efficacy in numerous cancer indications, including breast, prostate, liver, ovarian, and colon cancers.
* INSM-18 AT THE FOREFRONT OF NEW CANCER DRUGS....EVEN AHEAD OF PFIZER IN THIS AREA
On March 7, 2006, the Business Intelligence firm La Merie S.L. reported that antibodies are at the forefront of novel cancer therapeutics targeting the insulin-like growth factor-1 receptor (IGF-1R).
The report states that INSM along with giant Pfizer are among the leaders in this promising oncology research area. INSM-18 is a dual inhibitor of IGF-1R and Her2/neu and is the only clinical stage IGF-1R small molecule antagonist (phase I/II in prostate cancer).
http://www.pr.com/press-release/7579
ENDO 2006....On Tuesday, June 27, 2006, at this year's ENDO conference, INSM presented study results showing that Iplex is effective in increasing growth and improving glycemic control in patients with severe insulin-resistance syndromes, specifically Leprechaunism and Type A syndrome.
In another clinical trial, Iplex significantly improved height velocity in children with severe primary insulin growth factor-I deficiencies, the company said. Finally, a third study of the pharmacokinetics of Iplex in normal adults also showed positive results.
Iplex is already approved in the United States as a once-daily treatment for children with short stature associated with severe primary IGF-I deficiency.
http://biz.yahoo.com/bw/060622/20060622005174.html?.v=1
NOTE:
iPlex is a proprietary INSM drug product for the delivery of recombinant insulin-like growth factor 1 (IGF-1). It is administered as a preformed complex with a recombinant form of its natural binding protein, insulin-like growth factor binding protein 3 (rhIGFBP-3) or BP3.
BP3 helps regulate the distribution of IGF-1 and prevents IGF-1 excess. Uncontrolled IGF-1 has been linked to conditions as serious as accelerated cancer tumor cell growth.
DO YOUR DD
RDCM COULD BECOME JULY'S SOMERA........RADAR IT
PROFITABLE & STRONG OVERALL 2Q 2006 RESULTS WILL BE REPORTED SOON......per company
LOW FLOAT....
STRONG BALANCE SHEET...
TARGET: $4++ AFTER EARNINGS
RDCM HIGHLIGHTS:
- 80C/SHARE CASH
- NO LONG-TERM DEBT
- HAS WON SOME LARGE CONTRACTS RECENTLY
- PRODUCTS ARE IN HIGH DEMAND CURRENTLY BY CELLULAR OPERATORS.
- PUBLIC FLOAT IS RELATIVELY SMALL AT ABOUT 9M SHARES.
- P/S RATIO = 1.3
- 2006 P/E = 18
RDCM provided the following guidance for 2Q 2006 to be reported in about a month:
...."Management projects that its revenues for the second quarter of 2006 will range between $6.0 million to $6.5 million...."
[This would generate net income of 4 - 6c/share depending on the revenue.
Compare these figures with 2Q 2005 revenues of $4.84 and net income of 1c/share.
I believe that RDCM could go over $4/share after 2Q 2006 earnings release.
During 2Q 2006, RDCM announced a multi-million $$, multi-quarter contract with Partner Communications Company Ltd. (NASDAQ: PTNR).
PTNR is a leading Israeli mobile communications operator providing GSM/ GPRS/ UMTS services and wire free applications under the brand. PTNR selected Radcom's UMTS monitoring solution. The Omni-Q system enables Partner to manage 3G service performance across various local sites from a single control center.
"Our Orange(TM) subscribers, currently numbered at over 100,000, demand high service quality and RADCOM's quality monitoring system helps us maintain it," said Alon Berman, Vice President Technologies for Partner.
"We are leading Israel's 3G revolution by offering a wide range of 3G services, and this investment in quality demonstrates our commitment to ensure customer satisfaction."
http://biz.yahoo.com/prnews/060410/ukm005.html?.v=54
RDCM has been punished severely for having reported a small loss of $119M in 1Q 2006. I believe that a strong bounce will start next week and will continue into anf after earnings in mid July.
Commenting on 1Q 2006 results, Arnon Toussia-Cohen, President and CEO of RADCOM, said,
..."we are pleased to have achieved non-GAAP breakeven for the period, a testament to the soundness of our underlying business platform and lean expense model, and remain on track for achieving our 2006 growth objectives. With worldwide 3G deployments gaining momentum, demand for our comprehensive, powerful and flexible 3G service monitoring solutions continues to grow."
.."Interest has been particularly strong from cellular operators, as demonstrated by our recent win of a strategically important multi-quarter deal with Partner Communications Ltd. (NASDAQ: PTNR - News), Israel's GSM cellular service provider, and by the nationwide deployment that we are carrying out for one of North America's largest cellcos."
..."Mr. Toussia-Cohen continued, "In line with the strategy that we set for ourselves last year, we continue to focus on building our worldwide sales and marketing capabilities. To address significant emerging opportunities in the Far East, we have established strong channels and marketing partnerships in China and an initial presence in Korea, and are currently evaluating other Far Eastern markets."
ABOUT RDCM:
RADCOM develops, manufactures, markets and supports innovative network test and service monitoring solutions for communications service providers and equipment vendors. The company specializes in Next Generation Cellular as well as Voice, Data and Video over IP networks. Its solutions are used in the development and installation of network equipment and in the maintenance of operational networks. The company's products facilitate fault management, network service performance monitoring and analysis, troubleshooting and pre-mediation. For more information, please visit www.RADCOM.com.
DO YOUR DD
EVOL has won significant contracts during the quarter ending June 30. Therefore I believe EVOL might surprise the market when it reports 2Q 2006 in just a few weeks from now.
http://finance.yahoo.com/q/h?s=evol
Stephen Gartside, president and CEO, said in the company's 1Q 2006 earnings release:
"With the exception of the decline in first quarter revenue, we are pleased with our performance in the period. New order bookings, our leading growth indicator, increased for the third consecutive quarter, and we are anticipating continued strength in the current quarter, particularly in the areas of Activation and Numbering solutions. In the first quarter we won new Activation business with three large overseas customers and took into production our first Latin American customer, in collaboration with a new channel partner. In addition, we put new Numbering Solutions projects into production for three domestic customers. We are seeing a strong interest across our product portfolio and are optimistic about long-term prospects for converting that interest into sales, particularly in the area of wireless service activation.
ABOUT EVOL:
Evolving Systems, Inc. (Nasdaq: EVOL - News) is a provider of software and services to more than 50 network operators in over 40 countries worldwide. Its portfolio includes market-leading products for Activation, Number Portability, Number Inventory and Mediation. Founded in 1985, the Company has headquarters in Englewood, Colorado, with offices in the United States, United Kingdom, Germany, India and Malaysia. Further information at www.evolving.com.
Keep an eye on these 3 in July
I purchased FRPT.OB (FPI) a few months back and it is up already 200% from below $2.00 a share to over $6.00 a share. There is a good board on FPI on ragingbull just search for FRPT.
The bottom line for FPI is that they have the most survivable combat support light trucks, engineering vehicles and transports there are. They have already prototyped and are demonstrating a replacement vehicle called the MUV-R (pronounced Mover) for the Humvee while the larger companies are still working on the concept.
Revenue is growing fast. The government basically gives FPI contracts for as much business as they can handle but since there is a lot more business than FPI even with a huge ramp up of production can handle, they have begun partnering with other companies.
For the recent Iraqi Light Armored Vehicle contract, FPI has partnered with BAE. BAE was awarded the contract but FPI will produce about half the vehicles, gets all the parts and other support business and gets a license fee from BAE.
Within the next three months, FPI will likely be awarded new contracts for both the Buffalo and Cougar vehicles and a development contract for the MUV-R. It is likely that the MUV-R will be picked as the interim replacement for the Humvee in Iraq. sometime late this fall. FPI is already searching for a suitable partner because the volume of production will require a large physical plant and workforce.
Some Statistics:
FPI's Sales
2003 -> $6.25 million
2004 -> $10.27 million
2005 -> $49.7 million
2006 Q1 -> $34.8 million
2006 Q2 prediction -> $49 million ( * Solid low ball estimate based on production see note)
2006 Q3 prediction -> $58 million
2006 Q4 prediction -> $65 million
2007 conservitave Prediction $350 to $550 million
Note: FPI has announced 59 Cougar's and 6 Buffalo produced/delivered in Q2. These vehicles add up to around $49 to $52 million in revenue. In addition, FPI will get approximately $2 million in spare parts business. There are sometimes deliveries of additional vehicles not announced. Normal production of Buffalo vehicles would be 9 to 12. The lower production may be explained by the expansion of the production line for Cougar's and a draw down in man-power for the Buffalo lines. FPI is currently trying to hire an estimated 50 to 100 people based on it's employment adds many of which state multiple positions. If additional vehicles are delivered, then the revenue prediction would be low. BAE may pay a license fee to FPI in Q1 which would be additional revenue.
April Production announcement:
http://biz.yahoo.com/bw/060501/20060501005665.html?.v=1
May production announcement:
http://biz.yahoo.com/bw/060605/20060605005659.html?.v=1
June Production announcement:
http://biz.yahoo.com/bw/060703/20060703005185.html?.v=1
Employment Info:
http://www.forceprotection.net/about/employment.html?order=date_posted
Dear Marty,
Buy INSM and by ritch and happy....forever ;D ;D
day 07.08.2006....the start of the success ;)
-- 2Q 2006 REVENUES: $210K vs. $28K.....EXCEEDED ANALYSTS' ESTIMATES FOR 2Q
-- SOLID BALANCE SHEET & REASONABLE CASH BURN...CASH OF $48M ENOUGH TO CARRY COMPANY THROUGH MID 2007.....EXCLUDING ALL IPLEX SALES.
-- CEO......2006 WILL BE AN EXCELLENT YEAR....2007 A BREAKOUT YEAR...
-- PER PRIOR CC'S AND PRESENTATIONS THERE ARE A NUMBER OF CLINICAL RESULTS SLATED FOR RELEASE THE SECOND HALF OF THIS YEAR INCLUDING MIOTONIC MUSCULAR DISTHROPHY....INSM-18 CANCER TRIALS...BP3 CANCER TRIALS..
-- EMEA APPROVAL IN SECOND HALF...(THIS COULD CAUSE A 50C POP)
VERY LITTLE DOWNSIDE AT THESE PRICES IMO.....GOOD LUCK
LOTS OS BUYING TODAY COMPARED TO THE PREVIOUS 5 SESSIONS
I have counted 8 different threads started on this stock,
3 by you, started Today, then Feb 27,and 15May.
Not to mention the thread in Previous 3SOF Picks.
In Stock Picking you will find a 5 page thread running on this stock...here
http://www.3stocksonfire.org/trading/index.php?topic=2303.60
Why start a new thread when all you have to do is use the search to find a thread,and run an update with your comments to that thread that already exist. ???
Many traders here puzzle me here by starting new threads on a pick when we already have one running,If only they could use the search and do an update to what is there.
Many threads on the same pick is just clutter on this site.
The only time I see 2 different threads needed is ,
A thread for the Long side pick .
A thread for the Short side pick.
Anyways, good luck with your trades.
Here is the thread I spoke of .
Today's closing chart.
Somebody kick this clown off the board (-97) trader rating. Its obvious he doesnt belong here...
Thanks ahead of time. :-\
Maybe putting in a double bottom.
Let's watch....
Technicals
Last Price Quote is:
-7.56%below 13-day EMA
-19.61%below 50-day EMA
RS Rating: 5
Fundamentals
Key Data:
Market Cap (M): $108.16
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: 11/09/2006
Last Analyst Rating: Buy
I am seeing big buyers for the first time in several weeks....INSM has a pulse folks!!
NICE BOUNCE!!!!!!
http://stockcharts.com/gallery/?INSM
TERABEMO
YOU ARE A ZERO
WHY POSTING
YOU ARE A LOOSER
INSM IS HOT...HOT...HOT!!!
Have a look now...I know MACD is just below 0 and is bearish sign but .... INSM just broke Ma 50 (1.23). It surged 9.1% to $1.22 $ ....day after 1.27 $....
Volumes are better http://finance.yahoo.com/q/hp?s=INSM
Looks like a little rally has begun ? (!)
http://stockcharts.com/h-sc/ui?s=INSM&p=D&b=5&g=0&id=p20944242188
looks like a cup is forming...then..handle...then breakout
For all current INSM investment reports by lazard and CEU unterberg
http://stockpick.badongo.com...
Best,
Id.
Hello...,
up 12 % yesterday on beautiful volume !
Is INSM weaking up ?! ( Bullishhh by now...)
break MA 50 (1.16) and hit 1.32 yesterday with an open @ 1.11....
http://stockcharts.com/h-sc/ui?s=INSM&p=D&b=5&g=0&id=p
here's the agenda...mark it !
2H06 - 6 month dose ranging Phase II data on MMD (iPlex)
2H06 - Initiate Phase I in ROP in Europe (iPlex)
2H06 - Phase I/II data in prostate cancer (INSM-18)
Oct 12-15 - Data from Phase II study in HIV-associated lipodystrophy at ICAAC
11/6/06 - Patent infringement trial date
Dec 06 - Complete enrollment in Noonan's Syndrome
Dec 06 - Refrigeration stability data on Label
Today again...10 % gain
no news...good volume .....
are we going to Ma 200 ?
D. :)
Today's closing chart......
This pick had a up and running thread, and you have posted to it before.
Why start a new one ? ??? So many threads on the same pick is just clutter on the boards.
http://www.3stocksonfire.org/trading/index.php?topic=2303.60
....continue to grow....INSM goes up on no news ?! ? up 8%
http://finance.yahoo.com/q/bc?s=INSM&t=5d
Watch the volume !!! What is this interest ?!!! any idea, comments ... ? please
19-Sep-06 1.27 1.41 1.21 1.41 2,930,500 1.41
18-Sep-06 1.12 1.32 1.11 1.27 2,636,700 1.27
15-Sep-06 1.15 1.15 1.12 1.13 294,600 1.13
as of 10:06 today.....+1.000.000 shares traded ?!
Important Upcoming Dates :
2H06 - 6 month dose ranging Phase II data on MMD (iPlex)
2H06 - Initiate Phase I in ROP in Europe (iPlex)
2H06 - Phase I/II data in prostate cancer (INSM-18)
Oct 12-15 - Data from Phase II study in HIV-associated lipodystrophy at ICAAC
11/6/06 - Patent infringement trial date
Dec 06 - Complete enrollment in Noonan's Syndrome
Dec 06 - Refrigeration stability data on Label
Id... ;D
Here is the thread members should post their comments to .
With a prime example of traders gone wild by starting numerous new threads on this pick .
All these other threads that were started should be merged with this one!
Ramsburgh, Do us all favor and merge, Please.
"Thread clutter on the Boards" >:D
Now to route the main thread started by "Therman" to the top of the list.
Which all the rest of that board clutter should be merged with this one.
Ramsburgh ,Please Merge !!!!!!
Quote from: setravis on September 22, 2006, 04:59:58 PM
Now to route the main thread started by "Therman" to the top of the list.
Which all the rest of that board clutter should be merged with this one.
Ramsburgh ,Please Merge !!!!!!
I say ramsburg should just delete all the other BS INSM threads. They look to be just a bunch of rubbish anyways, especially the ones from terabemo
Quote from: setravis on September 22, 2006, 04:59:58 PM
Now to route the main thread started by "Therman" to the top of the list.
Which all the rest of that board clutter should be merged with this one.
Ramsburgh ,Please Merge !!!!!!
Thanks a lot Setravis ;) You saved me a lot of work finding these threads ;) (applaud)
- Merged -
Quote from: Ramsburg on September 22, 2006, 05:37:50 PM
Quote from: setravis on September 22, 2006, 04:59:58 PM
Now to route the main thread started by "Therman" to the top of the list.
Which all the rest of that board clutter should be merged with this one.
Ramsburgh ,Please Merge !!!!!!
Thanks a lot Setravis ;) You saved me a lot of work finding these threads ;) (applaud)
- Merged -
Obrigado, Rams ! Você é um cavalheiro e estudante. Se eu acho que mais deste tipo de
coisa, Eu apresentará isto a você. Uma vez mais, muito obrigado.
Eu espero que meu português seja onde você pode entender.
Cumprimentos,
Seu comerciante da mesma categoria ao grande 3SOF! ;)
Também aplauda a você! ;)
Hi Setravis ;)
I understood everything you wrote there ;) heheheh
Were you using some kind of online translator ?
regards, and have a great weekend !
No translator Rams !
Eu tenho uma filha que vive em Rio (Brasil). Ela tem cidadania de duelo. Ela é uma "Brazacana" ;D Eu uso para se viver lá !
Regards to you, and have a great weekend yourself !
Well I will provide an Insmed update on this thread and continue to use it from now on....
Have been holding INSM for 3 long months (very long for me ???) throughout its entire consolidation, primarily based on valuation. In fact I think the last 3 months consolidation of its low should provide a solid base for it to move up from here. Both MACD and RSI have been steadily improving throughout this time.
Last week we had a first strong move out of this base on solid volume, breaking through 1.30 resistance (which has already been re-tested and should now provide strong support) and the long term descending trendline. Since then the pps has been consolidating in a pennant, and I'm looking for an upside breakout from this shortly (although it could also morph into a flag here). First target is to get through resistance at 1.50, and I would not like to see it break down below 1.29 support again.
Will get stuck back into more regular updates on this one as I think we will start to see things get moving on INSM in the next couple of months.
Not a nice day for INSM, broke down from the pennant, which may be morphing into a falling wedge. Still it closed at critical support of 1.29. A move below this level today would be a bad sign IMO, as it took over 2 months to break above this. If it looks set to close below here today, I'm moving on to greener pastures.
Today should be really nice....
RICHMOND, Va., Oct 04, 2006 /PRNewswire via COMTEX/ -- Insmed Incorporated announced today that the U.S. District Court for the Eastern District of Virginia granted in part Insmed's motion to dismiss unfair competition claims brought against Insmed by Tercica, Inc. In a ruling today, Chief United States District Judge James R. Spencer narrowed the scope of Tercica's lawsuit against Insmed. In dismissing portions of the claims brought by Tercica, the Court found areas in which Tercica had not met its burden of establishing that the alleged statements made by Insmed constituted "false advertising" or violated Virginia law. While the court held that a number of Tercica's other factual allegations, if proven, would state claims for false advertising under federal and California law, in comments at the September 9 hearing, Judge Spencer noted that he felt "most if not all" of Tercica's case "could go out on summary judgment."
http://www.marketwatch.com/News/Story/St...
::) Id...
Well in classic style, INSM spent the first part of yesterday languishing around 1.29 support (probably to get the faint hearted to sell out) only to rally in the afternoon, up to a high of 1.38, and closing reasonably well. Makes a nice bullish engulfing candle on the chart. ;)
ID, thanks for the PM yesterday, not sure about the C&H formation, as the recent rally didn't get close to the other side of the cup, plus it was already in a sustained downtrend. Also, I couldn't find the story you posted above, will see if anything hits the wires today. However, it would be very nice to see some continuation and a break out of this wedge with a bit more volume today - we'll see what happens. My target is still set around the 200 SMA, around 1.7 for the moment, alhough if we do get a pop on volume, I might sell into it.
Scotsman,
Nice job on the analysis. Applause. Looks like you got your morph, into the Bullish Falling Wedge. The "W"-Bottom target of 1.53 MADE. This would be a second bullish pattern breakout here, if it can move higher.
Quote from: ScottishTrader on October 05, 2006, 07:24:03 AM
My target is still set around the 200 SMA, around 1.7 for the moment, alhough if we do get a pop on volume, I might sell into it.
Sounds like a good idea. The Bullish Falling Wedge breakout would put 1.61-1.63 IN PLAY.
INSM has made a move out of The Scotman's Bullish Falling Wedge on nice volume: 234,000 shares on the first five minute bar into the 1.40s. 100 day average volume is only 583,000 shares, so that's pretty good.
Jumped in @ 1.39!
10:42AM Insmed announces that the U.S. District Court in part Insmed's motion to dismiss unfair competition claims brought against Insmed by Tercica (INSM) 1.37 +0.02 : Co announces that the U.S. District Court for the Eastern District of Virginia granted in part Insmed's motion to dismiss unfair competition claims brought against Insmed by Tercica. In a ruling yesterday, the co says Chief United States District Judge James R. Spencer narrowed the scope of Tercica's lawsuit against it. In dismissing portions of the claims brought by Tercica, the Court found areas in which Tercica had not met its burden of establishing that the alleged statements made by Insmed constituted "false advertising" or violated Virginia law. The co says while the court held that a number of Tercica's other factual allegations, if proven, would state claims for false advertising under federal and California law, in comments at the September 9 hearing, Judge Spencer noted that he felt "most if not all" of Tercica's case "could go out on summary judgment."
Quote from: Se7en on October 05, 2006, 11:16:25 AM
Jumped in @ 1.39!
Se7en,
MACD is positioned here for a nice Slap Shot to the upside if INSM can hold the breakout, and rally. Good luck!
INSM committed to The Scotman's Bullish Falling Wedge breakout, but closed on a dumb note, at 1.38. :P
The top trendline of a Bullish Falling Wedge generally has a fairly steep slope, so a stock can simply trade sideways and eventually just "fall over" the trendline without truly breaking out, so I view them as suspect until the stock clearly moves higher.
There were 3 data points to that top trendline, so it's a validated trendline. The last "hit" to that trendline was 1.39, so I view that particular price as important. INSM took it out yesterday morning on the big volume push to 1.42, which was good, but it didn't manage a CLOSE above it.
Total volume on the day was double average daily volume, so that's fine.
MACD did tick higher above the signal line, poised for a bullish "slap shot," so that's fine, too. (See yesterday's MACD chart posted above).
Since August 28, the 13/21 RSIs have have FOUR bounces out of Bullish Synchronicity (see next post). That looks good.
INSM now needs to capitalize on those good technicals. PRICE needs to move higher here. Target: 1.61 is IN PLAY.
Suggested stop: 1.25. That's a penny below the Bullish Falling Wedge pattern, and also would take the stock back below the 1.29 - 1.28 highs of the W-Bottom breakout. :P
Good luck to those long!
13/21 RSIs
Hey Melf,
Didn't get the chance yesterday to say thanks for your input - it is always good to have you around, and I really appreciate your analysis. I garee though - wasn't to enamoured with INSMs movement in the afternoon - after what should have been very positive news regarding one of their legal battles with TRCA, INSM ended up just over 2% while TRCA was up over 8% - doesn't make sense to me...
I'd like to hold INSM longer, but I have just decided to change my brokers, and so need to liquidate my account (my awful UK broker charges me £15 or over $25 per US trade and I can't trade half the stocks I want to) so if we get a short term move into the 1.40s I may sell into that strength (unless it looks REALLY strong) or if it heads below 1.35, which would suggest it is pullling back into the wedge, invalidating the continuation pattern. Can't believe I held this one for so long for just over a 10% gain, but a gain is a gain right?
Quote from: ScottishTrader on October 06, 2006, 08:32:40 AM
or if it heads below 1.35, which would suggest it is pullling back into the wedge, invalidating the continuation pattern.
Scotsman,
I show the top of the wedge coming in today at 1.315. It falls 0.01875 per day, so it will come in on Monday, October 9 at
1.29625.
That's the
1.29 - 1.28 top of the W-Bottom breakout, so since it was sloppy and went below that on the print of 1.26 at the bottom of the Falling Wedge, I suppose that it could go down there to "get it right" this time, but....UGH, if it does, unless it bangs higher very quickly. If it closes down there, that likely would turn the MACD down, etc. UGH...
Quote
Can't believe I held this one for so long for just over a 10% gain, but a gain is a gain right?
Absolutely! :D ;)
Quote from: Melf Elf on October 06, 2006, 08:56:45 AM
That's the 1.29 - 1.28 top of the W-Bottom breakout, so since it was sloppy and went below that on the print of 1.26 at the bottom of the Falling Wedge, I suppose that it could go down there to "get it right" this time,
That's what we got. Friday's low was 1.28, and INSM closed it out on a Bullish Hammer, and also put in Data #4 of a Bullish Falling Wedge, a fractal (repeating pattern) of The Scotsman's original Bullish Falling Wedge.
So, hopefully, INSM "got it right this time." :D ;)
The Bullish Falling Wedge combo comprises, and thereby is nested within, a Symmetrical Triangle, which "should be" a Bullish Continuation Pattern of the W-Bottom Bullish breakout, especially since
1.28 has held, so far.
I'll post that chart next.
Quote
but....UGH, if it does, unless it bangs higher very quickly. If it closes down there, that likely would turn the MACD down, etc. UGH...
UGH. We did get the downturn in MACD, which bugs me, but it's still above the zero line, so it could be alright. My fasterst RSIs, the 13/21 had an "Oops!" and are at Bearish Synchronicity, so if Friday's 1.28 low (sell pivot) gets taken out, that indicator will issue a short-term sell signal.
I'll post that chart after the Symmetrical Triangle.
Quote
We can see that, coming off the bottom, when the short-term 13/21 RSIs came into Bullsih Synchronicity, we have gotten a bounce higher.
This time, we got an "Oops!." The 13 went below the 21.
In past charts, we've seen where an "Oops!" has turned out alright. The faster RSI moves back above its "shadow," the next number down in the Fibonnaci sequence.
The 13/21 RSIs now are at Bearish Synchronicity, after the "Oops!" The 13 needs to power through it.
At Bearish Synchronicty like this, I use the prior day's low, which is 1.28, as a "sell pivot," meaning that if 1.27 gets printed, a sell signal is issued, then I decide whether I want to take the signal, or not.
Since the low of The Scotsman's Bullish Falling Wedge is nearby, at 1.26, I won't sell 1.27. But, I definitely will sell 1.25, which would indicate that we're likely going down to the Kumo (Cloud), which we'll see in the next chart.
INSM is beautifully positioned for a Bullsih Continuation breakout, with the Bullish Falling Wedges nested within this Symmetrical Triangle, with the faster 8-Day Tenkan Sen (solid green line) bullishly positioned above the 22-Day Kijun-sen, and with INSM bullishly positioned above the Kumo (Cloud).
If INSM can't capitalize on this, and takes out the 1.26 low of The Scotman's Bullish Falling Wedge, with the 13/21RSI issuing a sell signal out of Bearish Synchronicity, UGH....
Where does it look "likely" that we're headed? ???
We'd be back below the "W" Bottom breakout, and with that Kumo (Cloud) below here, a break of 1.26 suggests a re-test.
That still could be okay, longer-term. I created a line (dotted blue) parallel to the highs, that would form a channel. If the current Symmetrical Triangle morphs on us, I'd expect support somewhere down there.
That said...
>:D BREAK OUT ON MONDAY, YOU DEVIL >:D
Hey Melf, thanks for bring this back up the ranks on my watch list. It does look like a nice setup. Will be watching Monday. (Appl)
Time for that 50ma to cross 200.
uc.
Am out of INSM for now, in fact out of everything as I take a break while changing my trading accounts.
Have been singularly unimpressed with INSM's lack of strength in the last couple of weeks. I was expecting more continuation strength after the initial breakout. I know these patterns take some time to play out, but it looks to me like INSM could easily tag the 50MA (at 1.23) again as part of a larger falling wedge.
If that happened, I have to admit it would be an excellent buying opportunity. However, I would not like to see it close below key support at 1.28. a move right now above 1.35 would suggest a breakout of the falling wedge, but I would really like to see INSM break 1.40, which has caused some problems of late. The other problem I have is with the evolution of patterns - what I thought was a very bullish looking pennant consolidation (shown in green) broke to the downside, only to morph into a falling wedge, which should also potentially be bullish, but my feedling now is a bit of a "who knows?"
Usedcasting's weekly chart is more encouraging, as it shows the successful breakout and re-test of descending support and small pennant consolidation above key support. I also like the fact that the price has been holding above the midline of the BBs on a closing basis for the first time since it broke below 2.00 back in March. Finally, both MACD and RSI are looking much more positive. However, reading (and trading with) signals on weekly charts require one thing: patience, often a hard thing to have in these markets, and a willingness to let your money sit there as the situation evolves. For me, I let my money sit there for 3 long months, and really I feel the need to make it work a little harder.
For now I'll wait for the breakout, accepting that I may have to take a higher price.
Melf, I like your enthusiasm for INSM. I believe the break out will happen when some volume comes in... With these Bio pharms we need some news, and when/if we get some INSm is poised for a nice break out i believe
Scotts, thanks for watching while you take care of business, I hope all goes smoothly and you are back in the game quickly.
Cheers Joe
Quote from: joet on October 15, 2006, 02:58:22 AM
Melf, I like your enthusiasm for INSM. I believe the break out will happen when some volume comes in...
Joe,
I like "nested" patterns, or multiple patterns, ala ATI and INTC, recently, but naturally, these continuation patterns actually have to breakout (1.34 for the second Bullish Falling Wedge...1.35 for the Symmetrical Triangle with the nested Bullish Falling Wedges),
then continue . :D
Quote
With these Bio pharms we need some news, and when/if we get some INSm is poised for a nice break out i believe
Right.
It's got head room between here and serious resistance in the 1.60s (which is where the highest of the bullish targets would be, at 1.61 and 1.63),, and it has got the fire power of these bullish patterns, with which to get there,
if it breaks out!Given the short-term weakness in the 13/21 RSIs, we could be in for some more frustrating morphing, as The Scotsman pointed out, like a morph into a Bull Flag at the 50 DMA, which currently stands at 1.22.
The next measures of RSI, stepping down the Fibonacci sequence, are the 21/34RSIs, and they still look fine and have some room on the downside to come into Bullish Synchronicity, then bounce higher, if we should morph into a Bull Flag on the price chart.
Quote from: Melf Elf on October 15, 2006, 06:03:01 AM
Given the short-term weakness in the 13/21 RSIs, we could be in for some more frustrating morphing, as The Scotsman pointed out, like a morph into a Bull Flag at the 50 DMA, which currently stands at 1.22.
Here's what that would look like.
See the Green #4? The 50DMA actualy is at 1.2264 at Friday's close, and it's rising slightly each day since we're throwing out low numbers from 50 days ago, so it soon will be at 1.23.
For a Bull Flag morph, INSM would go down there, show us that the 50DMA is support,
then breakout of the Bull Flag.
Hmm-mm...
I think I'd better lower my stop, to allow for that possibility! :D
There's the 1.34 technical breakout of the little Bullish Falling Wedge. We need 1.35 for a breakout of the Symmetrical Triangle, with the nested Bullish Falling Wedges. And, some volume, please! :D
Quote from: Melf Elf on October 16, 2006, 12:26:25 PM
We need 1.35 for a breakout of the Symmetrical Triangle, with the nested Bullish Falling Wedges. And, some volume, please! :D
There's 1.35. Volume only is average, though, so we won't jump up and down. ::) ;D
Insmed Sues Tercica for False Advertising
Monday October 16, 4:15 pm ET
RICHMOND, Va.--(BUSINESS WIRE)--Insmed Incorporated (NASDAQ:INSM - News) announced today that it has sued Tercica, Inc. for allegedly false and misleading statements Tercica has made in advertising and promoting Increlex(TM), Tercica's Severe Primary IGFD treatment. In a counterclaim filed in the United States District Court for the Eastern District of Virginia, Insmed charges that Tercica has made numerous unlawful, false and misleading statements Increlex and/or IPLEX(TM), the only once daily treatment for children with short stature associated with severe primary IGF-I deficiency (Primary IGFD).
At issue are statements made by Tercica that Insmed believes are likely to mislead customers into believing that Increlex is a superior choice in Primary IGFD treatments. Those statements include misrepresentations that Increlex is the most convenient, stable and easy-to-handle Primary IGFD treatment; false statements that IPLEX requires "special equipment" or "elaborate thawing" procedures; statements that falsely minimize concerns about the incidence of severe hypoglycaemia during treatment with an IGF-1 drug (in contrast to Tercica's admissions to the FDA); and unfair and misleading price comparisons, which misrepresent the relative costs of using Increlex and IPLEX.
Insmed seeks an injunction barring Tercica from making these misrepresentations, an order compelling Tercica to recall its false advertisements and issue corrections, and an award of profits, damages, and attorney's fees and costs.
Insmed's counterclaim is part of its response to false advertising claims that Tercica brought against Insmed in June. Portions of those claims were dismissed by the Court earlier this month. The matter is scheduled for trial in March.
About IPLEX
IPLEX is approved in the United States as the only once daily treatment for children with short stature associated with severe primary IGF-I deficiency (Primary IGFD). IPLEX, a complex of recombinant human IGF-I and its binding protein IGFBP-3 (rhIGF-I/rhIGFBP-3), is the only FDA-approved IGF-I replacement therapy that also replaces deficient IGFBP-3 in these patients. The drug, which was launched in the second quarter of 2006, is also being investigated for various other indications with unmet medical needs, including severe insulin resistance, myotonic muscular dystrophy and HIV Associated Adipose Redistribution Syndrome (HARS). For more information about IPLEX please go to www.go-IPLEX.com.
About Insmed
Insmed is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com.
http://biz.yahoo.com/bw/061016/20061016006104.html?.v=1
Quote from: Se7en on October 16, 2006, 04:57:49 PM
Insmed Sues Tercica for False Advertising
Monday October 16, 4:15 pm ET
Se7en,
Kewl. 8) >:D
That's interesting timing, technically, isn't it? ::)
Quote
10:42AM Insmed announces that the U.S. District Court in part Insmed's motion to dismiss unfair competition claims brought against Insmed by Tercica (INSM) 1.37
That bit of news on October 5 didn't do much for the stock, other than to give it a little pop out of The Scotsman's Bullish Falling Wedge, which resulted in the sideways-to-down morphing into a SECOND Bullish Falling Wedge, from which we broke out of yesterday, on a closing basis.
On this news, INSM is better-positioned, technically, with our DOUBLE Bullish Falling Wedge nested with the Symmetrical Triangle, and with the stock sitting
right there , champing at the bit for a breakout. INSM broke out intraday yesterday, hinting that it wants to go higher, but couldn't close it out at 1.35.
I'd like to see INSM indicated at something like BID 1.36...ASK 1.37 at the open, right at yesterday's high, then take off to the upside.
In this technical situation, it almost doesn't matter what the news is. Just the fact that there
is news could spark buying interest from the momo boys, on a technical breakout. DNDN is similarly positioned for the open today, although it did breakout yesterday on a closing basis.
Maybe DNDN ought to get with the program, and sue somebody! ;D
Thanks for this news, Se7en. Applaud.
Here's the little Bullish Falling Wedge breakout. Targets: 1.42 and 1.49 are IN PLAY, as long as 1.28 isn't taken out.
EDIT: The Scotsman's Bullish Falling Wedge Target: 1.61 still is IN PLAY since the 1.26 low of that pattern hasn't been taken out.
TRIPLE Breakout of the two Bullish Falling Wedges and the Symmetrical Triangle, within which the wedges are nested.
Bullish Engulfing candle on the day, on 2 times 100 day average volume. This "should" get us going to the upside soon.
Upside Targets:
1.54 IN PLAY
1.61 IN PLAY
1.62 IN PLAY
Minor Targets of 1.42 and 1.47 also are IN PLAY
INSM still trading within the symmetrical triangle, I opened a position this morning at 1.31 looking to minimize risk in case it breaks down just below 1.30
GLTA
INSM will not be value fairly until the lawsuit cloud is gone. It might take months for that.
Whadda pain in the $#%#. :D
This looked very good, with the breakout of the nested patterns, but no volume and no upside follow-thru. :P
We're back in the channel. The low at Blue #2 it 1.26, and we're there, at the low of the day. If 1.25 gets printed I'll sell.
I didn't post the trade, but I wanted to follow-up on my posts in this folder.
It will be a 6% loss. :(
Quote from: Melf Elf on October 24, 2006, 11:38:59 AM
Whadda pain in the $#%#. :D
This looked very good, with the breakout of the nested patterns, but no volume and no upside follow-thru. :P
We're back in the channel. The low at Blue #2 it 1.26, and we're there, at the low of the day. If 1.25 gets printed I'll sell.
I didn't post the trade, but I wanted to follow-up on my posts in this folder.
It will be a 6% loss. :(
same here, I got stopped out already at 1.28....but that's what the plan was
Quote from: bocasva on October 25, 2006, 12:01:45 AM
same here, I got stopped out already at 1.28....but that's what the plan was
bocasva,
Good for you, for following your plan. Applause.
I expected to get knocked out of this trade, and likely will, but 1.26 held, so I'm still in it.
Melf...if you haven't sold...
Today will be the day I think ( 1.54 in play ? we'll see!...)
Have a look :
Former Amgen Manufacturing Executive Joins Insmed
Wednesday October 25, 5:05 pm ET
RICHMOND, Va.--(BUSINESS WIRE)--Insmed Incorporated (NASDAQ: INSM - News) announced today the addition of former Amgen executive Mr. Doug Farrar to Insmed's manufacturing operations in Boulder, Colorado as Vice-President of Insmed Therapeutic Proteins. While at Amgen from 1987 to 2005, Mr. Farrar had increasing operational and development responsibilities which included Process Development, Clinical Manufacturing and Commercial Manufacturing.
ADVERTISEMENT
With over 20 years of biotech industry operations experience including 18 years with Amgen, Mr. Farrar has produced over 20 products for use in Amgen clinical trials and has hosted numerous approval and periodic inspections for the FDA, Europeans and Health Canada. He has been involved in filing 11 Investigational New Drug (IND) Applications and 2 Biological License Applications (BLA). He has worked on dozens of products produced by recombinant DNA technology in microbial, yeast and mammalian cells systems. Doug's most recent role as Director of Manufacturing included responsibility for the successful transition of Amgen's very large scale Lake Center manufacturing plant from clinical to commercial production.
"I am excited to be joining the highly talented and innovative team at ITP and look forward to making significant contributions to the continued success of Insmed Inc.," said Mr. Farrar.
Insmed also announced that Mr. Dennis Lanfear has joined the Company as a Strategic Consultant focusing on production, commercialization and marketing areas. While at Amgen from 1986 to 1999, Mr. Lanfear founded the Process Development Department which became the preeminent organization of its type in BioPharma and a key strategic advantage for the company. During his tenure at Amgen, Mr. Lanfear directed efforts from post-discovery to Phase III for several development programs including wound healing, growth factors and neurotrophins. From 1986 to 1990, he managed Amgen's corporate product development relationship with SmithKlineBeecham. From 1990 to 1999, he managed and had direct budgetary responsibility for the $135MM development partnership with Regeneron Pharmaceuticals. He was also named vice president of market development where he defined long term competitive and reimbursement strategies for Epogen(TM), a multibillion dollar drug.
Mr. Lanfear is President of Lanfear Capital Advisors, focusing on investments in therapeutic product and device companies. He is also a Director of Anthera Pharmaceuticals, a clinical stage drug development company.
"The years of broad protein experience that Doug and Denny bring to Insmed Therapeutic Proteins will significantly enhance our Iplex(TM) commercialization capabilities," said Geoffrey Allan, President and Chief Executive Officer of Insmed.
http://www.genengnews.com/news/bnitem.aspx?name=7532494
Id...
Quote from: IdFix on October 26, 2006, 03:21:25 AM
Melf...if you haven't sold...
Today will be the day I think ( 1.54 in play ? we'll see!...)
Have a look :
Id,
I've been hanging on...by a fingernail. :D My 1.25 stop wasnt' hit.
Quote
"I am excited to be joining the highly talented and innovative team at ITP and look forward to making significant contributions to the continued success of Insmed Inc.," said Mr. Farrar.
Let's hope that the market gets as excited as Mr. Farrar. ;D
Thanks for that new, Id. Applaud.
Hi guys'
FYI..
Insmed to Present at Upcoming Conferences
Monday October 30, 4:56 pm ET
RICHMOND, Va.--(BUSINESS WIRE)--Insmed Incorporated (NASDAQ: INSM - News) today announced that Philip J. Young, Chief Business Officer of Insmed Incorporated, will present a corporate overview on Tuesday, October 31 at 10:30 AM ET during the C.E. Unterberg, Towbin Life Sciences Conference taking place at the New York Palace Hotel in New York City. He will also be presenting on Monday, November 6 at 4:55 PM ET at the Rodman & Renshaw 8th Annual Healthcare Conference at the New York Palace Hotel in New York City; and on Tuesday, November 28 at 9:30 AM ET at the Lazard Capital Markets 3rd Annual Life Sciences Conference, which is also taking place at the New York Palace Hotel in New York City
----------------------------------------------------------
http://www.fbo.gov/servlet/Documents/R/1573013
General Information
Document Type: Award Notice
Solicitation Number:
Posted Date: Oct 30, 2006
Archive Date: Oct 30, 2006
Classification Code: 65 -- Medical, dental & veterinary equipment & supplies
SetAsides:
Naics Code: N/A
Contracting Office Address
Attn: Department of Veterans Affairs National Acquisition Center, (049A1), P.O. Box 76, Building No. 37, Hines, Illinois 60141
Description
Contract Award Date: Jun 09, 2006
Contract Award Number: V797P-5906X
Contract Award Amount: $7,500,000
Contract Line Item Number:
Contractor: Insmed Incorporated, 4851 Lake Brook Dr., Glen Allen, Virginia, 23060
--------------------------------------------------------------
Today...
Jody LoMenzo Named Director, Investor Relations and Corporate Communications
Tuesday October 31, 8:15 am ET
RICHMOND, Va.--(BUSINESS WIRE)--Insmed, Inc. (NASDAQ:INSM - News) announced today that Jody M. LoMenzo has joined the company to serve as Director, Investor Relations and Corporate Communications.
ADVERTISEMENT
Over the course of her professional career, Ms. LoMenzo has served in senior communications roles for Fortune companies, start-ups, and non-profits, including: the medical-surgical division of McKesson Inc. as marketing communications director; United Dominion Realty Trust, as director of investor relations and corporate communications; Infineon Technologies (White Oak Semiconductor) as communications director; and as administrative director for marketing and public relations at Bon Secours Richmond Health System.
Ms. LoMenzo also has experience on the agency side, working as director of strategic communications for the public relations division of The Martin Agency. She owned and operated her own communications strategy firm, working with healthcare clients in biotechnology and pharmaceuticals to introduce and promote new drugs. Of note, her work with Genentech for the launch of tPA, SmithKline for its Hivagen test, Amgen for Neupogen, Fujisawa for Ganite, BristolMeyer-Squibb for Cardio Tec, Sandoz for Eldyprl, and Lederle for Suprax.
Ms. LoMenzo began her professional career in television, working in New York City, as a news editor for ABC-TV's Good Morning America and as associate producer at CBS News. She received an Emmy nomination while at WABC-TV for her work as special projects producer. A graduate of New York University, she resides in Richmond.
----------------------------------------------------
Sthg is on...let INSM fly now !!!!!
----------------------------------------------------
Id..... ;)
Quote from: Melf Elf on October 26, 2006, 08:23:20 AM
Quote from: IdFix on October 26, 2006, 03:21:25 AM
Melf...if you haven't sold...
Today will be the day I think ( 1.54 in play ? we'll see!...)
Have a look :
Id,
I've been hanging on...by a fingernail. :D My 1.25 stop wasnt' hit.
Sold INSM for a break even.
Id Fix,
Thanks for the updates. Applause.
Quote
Quote
Quote from: Melf Elf on November 01, 2006, 10:27:14 AM
[
I've been hanging on...by a fingernail. :D My 1.25 stop wasnt' hit.
Sold INSM for a break even.
It turns out that my 1.25 got hit today, and I woulda have had a 6% loss instead of the break even I took yesterday.
That's a coulda...shoulda...woulda that turned out okay. ;)
hi,
The third International Congress of the GRS and the IGF society
http://www.congre.co.jp/3grs-igf/
Exhibitors List :
E-1 Pfizer
E-2 Insmed
E-3 Eli Lilly and Company
E-4 Novo Nordisk Pharma
E-5 Serono International
E-6 Dainippon Sumitomo Pharma
Re: Info Coup
That's it, but inside...
The week of November 11 or the next may great us with a bombardment of good news! Fasten your seat belts! This is just a sampling with the relevant new formulation of iPlex and the Cecilia Camacho-Hübner study. I've also thrown in some Clemmon's March info. There are sevral more BP3 study presentations, but I leave that for all of you to read...the first link is the goody. Enjoy!
http://www.congre.co.jp/3grs-igf/images/program.pdf
PO14 IGF Clinical/Therapy
LP-92 Stability of rhIGF-I/rhIGFBP-3 under common storage conditions Kenneth M. Attie Dept. of Medical Affairs, Insmed Inc., Richmond, VA,
USA
OR08-4 The IGFBP-3 partner, humanin, protects beta cells from apoptosis in vitro and improves glucose tolerance in the NOD model in vivo Kuk-Wha Lee Department of Pediatric Endocrinology, Mattel Children's Hospital at University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, USA
OR08-3 Effects of insulin-like growth factor binding protein-3 on human malignant pleural mesothelioma cell growth and apoptosis Cecilia Camacho-Hübner Department of Endocrinology, William Harvey Research Institute and St Bartholomew's Hospital, University of London, London, UK
http://grc.org/programs/2007/insulin.htm
David Clemmons a Lead investigator for Insmed...diabetes
Re: Info Coup
No takers on the OR08-4 presentation?
"IGFBP-3 partner, humanin, protects beta cells from apoptosis in vitro and improves glucose tolerance in the NOD model"
If IGFBP-3 "holds" humanin for delivery...Alzheimer's
http://www.pepnet.com/humanin.html
Therefore: a lot of interesting news: as you can see the Alzheimer stuff is still in mice tests just like the Herceptin/BP3 Breastcancer tests discussed here a couple of months ago. But again it's a sign of the possibilities INSMEDs product portfolio brings.
Also: nice to see that INSMED is exhibiting between big guns in pharma, it's a recognition of the eminent work done by INSM in the field.
(http://\\assurancetourix\xavier.bastin$\mes%20images\iinsm.jpg)
Id
Id,
I would wait for the CCI to give a buy signal first before considering it. All in all INSM still has a bearish tone and a lot of uncertainty in the air. I am waiting for INSM to show me something positive, rather than try and pick a bottom for now.
agreed Scott.
...
I have the time with this one...
and am bit nervous also....When The freakin jury's trial will be ended...the stock will move, perhaps before if you read what I post...
Buy on rumors...sell on news ? ::)
IdFix
nice move at the end. with huge volume. resolution to the trial..we shall see.
Id,
dunno what happened there, but you were bang on the money - hope you got some!!!
Hi,
Good volume again on friday,(is sthg on ??)
10-Nov-06 1.28 1.35 1.24 1.33 3,203,900 1.33
9-Nov-06 1.35 1.38 1.25 1.28 1,638,100 1.28
8-Nov-06 1.20 1.40 1.19 1.37 2,647,400 1.37
7-Nov-06 1.21 1.24 1.19 1.19 809,900 1.19
6-Nov-06 1.25 1.28 1.18 1.22 1,607,600 1.22
---------------------------------------
INSM was presenting on November 11th at Kobe , Japan their new room stable form of iPlex. ....
+ end of jury's trial expected on 22/11..
--> this could be really interesting ...MMMmmh
We'll see !
-----------------------------------------
(http://C:%5CDocuments%20and%20Settings%5CRaymond%5CMes%20documents%5CMes%20images%5CINSM%201211.JPG)
-------Id...
Id,
I like it, Volume is always a very good sign of something cooking. A close above 1.36 would suggest INSM is finally ready to break out. As we all know, any number of news related factors could propel this one significantly upward.
I may look to enter a position on Monday.
Cheers for keeping the INSM thread on the boil!
INSM is on fire and I like it!!!
Has broken out of the recent falling wedge and has got above 1.47-1.48 resistance. A close above here would bode very well. I am not sure whether this is related to the trial or what, but I like it and am back in. Averaged in at 1.45. First target, 1.60.
Not such a great close, at 1.46, INSM couldn't hold onto its earlier gains. However, 1.50 was broken and I think we will be back there shortly, and the long term chart suggests 1.45 should be support. Upcoming resistance at 1.54-55, and 1.65. Volume is still very solid, above 3m, I think she finally wants to move. Really any news pending the trial could kick this one off, and the 1 yr chart shows clear potential.
INSM can be volatile, so I will go with a 1.29 stop for now, just below the upper trendline of the flag and the 50SMA. This quite a bit of risk for this trade, so I will look to move it up if we get support confirmation at 1.35 or 1.40. The flag breakout puts a target of 1.70 in play.
Here is a 1 yr semi-log chart:
INSM update:
Following the breakout of the recent falling wedge pattern, INSM rallied up to the pattern resistance at 1.54 and has pulled back the last couple of days, also tagging 1.35, confirming this level as support within the current move. Fridays candle suggest some indecision in the market on INSM, but the falling wedge target of 1.70 is still in play provided the pattern brekout level holds at 1.34. Looking at the 30 minute chart, there is also a recent ascending trendline forming with 3 tags, that may support further advances. Volume in the last 2 weeks is also up significantly, with big volume on the up moves and low volume on the pullbacks, which is provides encouragment that INSM has legs to go further.
I'm beginning to think that INSM is potentially a very high risk play right now, as pretty much everything hinges on what happens in the patent infringement case. From what I have read, it appears that INSM has a fairly strong chance on winning at least some of the patent issues - whether they will come out with a clean sheet remains to be seen. In any case, I am trying to be more risk averse in my trading, so I may sell a portion of my position if I can get a price above 1.45 in the next day or 2, simply to limit the risk. The stop for my position will be set at 1.33, giving me just over 8% risk on the trade, barring any gap down. the chart looks quite positive right now, but with heavily news driven stocks like this (and we know what bad news does), anything can happen.
Big move for INSM today, 1.70 falling wedge target MADE. Looks good - it seems this must be related to expectations surroundinga positive resolution of the trial. I'm holding my position for now.
~~I'm holding my position for now~~
Me too Scottish...and 'm waiting the trial to be ended this week .
PR released Friday or Monday.
Watch the volume today ! >:D
Nice to see you still here ! ;)
What about tomorrow's activity ???MMMmmmmmh, we'll see !
Cheers,
Id...
Quote from: ScottishTrader on November 21, 2006, 03:03:13 PM
Big move for INSM today, 1.70 falling wedge target MADE.
Scotsman, Id Fix and soxguy,
It sure did!
I figured that it would
finally quit morphing, once I sold it. Curses! >:D :D
Nice job, guys. Glad to see it rallied for you. Applauds.
Hey Id,
I would really prefer it if you didn't keep posting links to our 3sof analysis on the Yahoo MBs. While I know that that is how I first found 3sof, I would rather keep our analysis and our ideas within our community. I really don't want all the pumping idiots heading over here, especially from the INSM board (which while it does have a lot of good info, also has some real idiots).
Thanks,
ST
Sorry...
wanted to educate them . :-[
don't bother, it really isn't worth it...
by the way, sold 1/3 of my position this morning to protect some profits. Still think it will go higher by next week. Good luck to us ;)
Another monster day for INSM with ridiculous monster voulme - I'm really liking this buy the way (despite selling some). Just thought I would put a heads up here for that slightly nasty looking 1.83 gap to crap resistance that we just kicked our heads against today from the June fakeout rally. It could cause some problems, but if the trial is dismissed and things get crazy, it shouldn't be a problem. We are also heading into "sell the news" territory, so we may see a sell-off when the trial PR comes out regardless of the outcome. I'm working on being prepared for any eventuality and am raising my stop to 1.59. Above 1.83, I think we may see resistance at 2.00 (well, duh) and 2.10 above that, but if we got to $2 I would be veeery happy (though really I wanna see 3, but lets not get ahead of ourselves here...) Anyway, here's the chart update:
Those who are interested by the Jury's trial which opposes INSM to TRCA/DNA....
(The verdict will be known next week)
Insmed was accused to infrige 3 patents...n°151, 287 and 414
INSM doesn't infrige the 151 and 414 patent :P
http://www.xs4all.nl/~surg3on/2006-november-INSMvsTRCA_trial_motions/961%20defendants%20Memorandum%20in%20Opposition.pdf
INSM doesn't infrige the 287 patent also :P
---DEFENDANTS' MOTION JUDGMENT AS A MATTER OF LAW RE: FAILURE TO ESTABLISH INFRINGEMENT OF THE '287 PATENT
Case No. C-04-5429 (EMC)
.v
WASH_1749406.1
DM_US\8411641.v2
HOWREY
LLP
I. INTRODUCTION
Defendants INSMED INCORPORATED, CELTRIX PHARMACEUTICALS, INC., and
INSMED THERAPEUTIC PROTEINS, INC. ("Defendants" or "Insmed") respectfully submit this
Motion for Judgment as a Matter of Law Re: Failure to Establish Infringement of the '287 Patent
pursuant to Federal Rule of Civil Procedure 50(a). GENENTECH, INC. and TERCICA, INC.
("Plaintiffs" or "Genentech) have been fully heard on their claim that Insmed has infringed the asserted
claims of U.S. Patent No. 5,258,287 ("the '287 patent") and they have failed to meet their burden of
proving infringement of the '287 patent. The Court is respectfully requested to grant judgment as a
matter of law in favor of Defendants on the grounds that, based upon the evidence presented, no
reasonable jury could find that Defendants infringe the '287 patent. Plaintiffs claim of infringement of
the '287 patent should thus be dismissed.
------
So... it seems that the case is O.V.E.R ...
-->Inequitable conduct hearing next Wednesday
Waiting for the Court's decision..last step !...
The stock will move up seriously ...if it's ok 4 us
To follow >:D
IdFix....
short term,it all depends on this trial. obviously good news is anticipated. i'm trying to look down the road. they have other drugs in the pipeline i believe. anyway,the recent increase in the pps has justified my reasons for staying long at all. a side note..when i read micheal's call on aspv, in minutes i sold my sai and bought aspv at 17.73. of course it went down the next day. but i'm optimistic. also in rnvs too. that's long term. we shall see. i get into something like that because of plays like pozn which i focused on when it declined ,then i lost track of. since it's thanksgiving here in the states,you may not have what you want, but be thankful for what you have. soxguy
Further continuation on Friday of this move on very strong volume: over 14M shares traded this week and up over 30%, now that is a stock on FIRE!!! Obviously it all comes down to the trial this week, but as I said elsewhere, just look at TRCA in comparison: less than 500k traded and it is down 1% for the week. I think we know where the smart money is hedging their bets on this one. I doubled my position in INSM on Friday as it broke through key 1.83 resistance, and regardless of what happens with the case I will sell half my position when the trial results come out. I wouldn't be surprised to see a big gap up and "sell the news" if it comes out favourably - a lot of people have held losing positions in INSM for a long time. But longer term, with the trial out of the way, things should start looking better for INSM. All aboard!! Choo choo!! :D :D
Golden Cross soon ?
Insmed will be on fire today ...2$PM...I like this ! >:D
(http://\\assurancetourix\culture.la-gb1$\mes%20images\sans%20titre.jpg)
;)
That legal action from Genentech and Tercica was always a cloud on INSM. If that issue gets out of the way, hopefully to the better for Insmed, it is a positive development.
The 66% rally in November was discounting that possibility, not yet confirmed (hence the recent decline).
If we get good news, probably the stock will trade around $2 again. If the news is negative it will tank hard, probably 15 or 20% in one day.
It is essential that the court ruling turns out positive for INSM, but it doesn't solve other problems, like the $158 M market cap without relevant revenues and the constant need to make private placements (well, not soon, as their balance sheet is strong now).
My biggest concern is the market size of iPlex. When I first bought the stock I thought it was much larger. I thought the drug was to make small children grow more, so nobody would be less than 150 cm tall when an adult (I know you don't use the metric system, but I don't know your system). Anyway, on my limited information I expected iPlex to help short children grow more, but no, after all it is just for a small number of children that suffer of Severe Primary IGFD. I remember there were just 20 or 30 thousand children with the disease in the US.
With the current information I don't see a big potential on the stock, but good luck for everybody holding :)
Verdict is out:
QuoteGenentech Inc
Insmed Infringed Genentech Hormone Patents, Jury Says (Update1)
By Joel Rosenblatt
Dec. 6 (Bloomberg) -- Insmed Inc., a maker of drugs for endocrine disorders, infringed three patents covering a treatment for abnormally short children, a jury said today in a lawsuit brought by Genentech Inc. and Tercica Inc.
The jury in Oakland, California, federal court awarded Genentech and Tercica $7.5 million in damages and a percentage of future sales of the treatment. Insmed shares fell 11 percent, or 17 cents, to $1.42 at 3:25 p.m. in Nasdaq composite trading.
Insmed's Iplex and Tercica's product, called Increlex, are growth drugs used to treat about 6,000 short children who don't respond to normal human growth hormones. The drugs also have off- label uses, such as increasing body mass. Tercica paid a licensing fee to Genentech, the world's second-biggest biotechnology company, to manufacture Increlex.
The jury verdict was ``disappointing but not surprising,'' said Henry Bunsow, a lawyer for Insmed. He said he would appeal. Lawyers for Genentech and Tercica asked the court today for an injunction barring future sales of Insmed's treatment.
Genentech and Tercica sought damages of $10 million, receiving $7.5 million as part of today's verdict. The jury also awarded the plaintiffs a 15 percent royalty, or as much as $15 million, on the first $100 million of Iplex sales. Genentech and Tercica also received a 20 percent royalty, or as much as $20 million, on the second $100 million of Iplex sales.
$1 Million
Genentech shares fell 47 cents to $83.05 at 3:25 p.m. in New York Stock Exchange composite trading. Tercica shares rose 17 percent, or 89 cents, to $5.99 in Nasdaq composite trading. Insmed has had $1 million in sales of the drug since its introduction, said Terry McMahon, a lawyer for South San Francisco, California-based Genentech and Brisbane, California- based Tercica, during closing arguments.
Richmond, Virginia-based Insmed argued Iplex was researched for more than 20 years and that it was made and approved by regulators with respect for existing patents.
In June, U.S. District Judge Claudia Wilken ruled Insmed infringed one of the three disputed patents, leaving the remaining claims for the jury to decide.
The case is Genentech Inc. v. Insmed Inc., 04-cv-5429, U.S. District Court, Northern District of California (Oakland).
To contact the reporter on this story: Joel Rosenblatt in Oakland federal court at [email protected] .
Last Updated: December 6, 2006 15:29 EST
back over $1.00 watching for news!
on fire >:D >:D >:D
Insmed "buy"
Monday, February 19, 2007 4:07:30 AM ET
Lazard Capital Markets
NEW YORK, February 19 (newratings.com) - Analysts at Lazard Capital maintain their "buy" rating on Insmed Inc (ticker: INSM). The target price is set to $3.
In a research note published on February 16, the analysts mention that as a result of stipulation submitted to the court by Insmed and Tercica, the preliminary injunction hearing has been delayed. The reasons for the delay in the hearing and when it would be scheduled appear uncertain, the analysts say.
&
NY Times link:
http://www.nytimes.com/2007/02/17/business/17patent.html?pagewanted=1&_r=2&adxnnl=0&adxnnlx=1171689804-cCSu2o39xZKTw6O3aer7oA
on fire !!
anybody invested?
Ive got 4k shares I've held for awhile Laonda. I hope TRCA, DNA, and INSM can come to some agreement as the Doctor expressed in the NYT article. I really don't know what to believe as far as the lawsuit. I've read a lot about it, but opinions obviously vary. All I know is that I have 3 children, and if I had a chance to give my child 1 shot a day instead of 2, there is no way I would opt for 2, so IPLEX IMHO is going to get a lion share of the patients choosing between Increlex and Iplex, the 2 approved drugs, but the lawsuit just hangs ove the head of the stock like a disease.
I'm still holding...with a 40% loss >:( >:( >:( >:(
So go INSM go
Amarens
There's a gap and a pseudo gap to be filed.... :-\
(http://\\assurancetourix\christiane.leclerc$\mes%20images\sans%20titre.jpg)
I'm still in also. I have a habit(bad?) of buying on the way down if i believe in the stock. Sitting on a 14% loss,which may turn into a gain in the very near future. Patience is indeed a virtue. GLTA! soxguy
insm up 20% after hours. Watch it tommorow. soxguy
insm up in premarket. No news,just speculation.
nice INSM chart on no news
fyi:
latest analyst report:
Insmed "buy"
Monday, February 19, 2007 4:07:30 AM ET
Lazard Capital Markets
NEW YORK, February 19 (newratings.com) - Analysts at Lazard Capital maintain their "buy" rating on Insmed Inc (ticker: INSM). The target price is set to $3.
In a research note published on February 16, the analysts mention that as a result of stipulation submitted to the court by Insmed and Tercica, the preliminary injunction hearing has been delayed. The reasons for the delay in the hearing and when it would be scheduled appear uncertain, the analysts say.
I'm sure this is the take of a bagholder, but this is a buy at .89 If it dips below, I will do the unthinkable and average down and then hold.
Short stature was not what was going to make IPLEX huge in the first place, and now the lawsuit is put to bed, and DNA is motivated to help in the future. The 7.5 million judgement goes away, and the path is cleared for the big money to be made down the line free the lawsuit cloud. I had hoped for a buyout settlement, but dems da breaks.
The problem is that they now have no drug on the market - i.e. no revenues (I know, revs from IPLEX to date were pretty paltry), are cutting their workforce substantially, have very litle cash, so we can expect further dilution in the coming months, have to split revenues from IPLEX with TRCA/DNA for further indications... the list goes on and on. People are shouting that they will make $300M a year from IPLEX in Italy, but this is totally unrealistic. I really think INSM is in deep trouble now, and I would wait for the dust to settle before buyin any more. It could easily go down to .50 before basing. We have all seen what happens to Biotechs when bad news hits them, especially when they have little or no revenues. They get creamed.... and then they get creamed some more. Just look at BBC (Bodisen Biotech). The only thing htat absolutely shocked me yesterday, was that I realised I could short INSM!!! Wish I had known that earlier!!
What I think is so strange is that INSM was one of the only stocks to be rallying last week when everything else was getting killed. This kind of contrarian movement is difficult for me to understand, with the news we now know has come out. Perhaps funds that were "in the know" were pumping INSM up, knowing it is the kind of company that has a strong enough following among traders who will dive in based upon price movement alone, only to take them to the cleaners?
Technically, there should be support at .85, and .90 is a key level as well, but I really think it may be a long time before we see INSM trading above 1.20 again.
Just my thoughts (and I have put my money in INSM many times, and mostly lost my shirt on this one, if I do say so myself)
This one moving in the pre-market.......
+21.57%.......Volume @ 474,500
Press Release Source: Insmed Inc.
Insmed Releases Positive Results from IPLEX Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
Monday April 30, 9:00 am ET
RICHMOND, Va.--(BUSINESS WIRE)--Insmed Inc., (Nasdaq:INSM - News) today announced positive results from a Phase II investigator-sponsored clinical study of the company's drug IPLEX(TM) in HIV-infected patients affected with HIV-associated Adipose Redistribution Syndrome (HARS).
Preliminary results from the study, being conducted at the University of California, San Francisco, showed that three months of 0.5 mg/kg/day IPLEX treatment in seven patients increased IGF-I levels 3-fold and was associated with significant improvements in fasting glucose levels, the amount of insulin secreted during an oral glucose tolerance test, and overall insulin sensitivity. Moreover, there was a significant reduction in trunk fat and a positive downward trend in waist circumference when compared to baseline. Lipid profiles also tended to improve.
Notably, normal glucose tolerance was restored in half of the six patients diagnosed with impaired glucose tolerance (IGT) at the start of the study. These IGT patients also experienced a significant decrease in visceral adipose tissue (VAT). Impaired glucose tolerance is characterized by blood glucose between 140 and 200 mg/dl at the 120-minute measurement of an oral glucose tolerance test. The next phase of the study is underway to explore an IPLEX dose of 1.0 mg/kg/day given for six months.
"Our study has demonstrated that a low dose of IPLEX increased IGF-I levels 3-fold and positively impacted abnormal glucose metabolism, dyslipdemia and abnormal fat distribution, which are present in a significant number of HIV patients treated with highly active antiretroviral therapy (HAART)," said Morris Schambelan, M.D., the study's principal investigator and professor of medicine and director of the General Clinical Research Centers at University of California, San Francisco, and chief of endocrinology at San Francisco General Hospital.
"We are very encouraged by these preliminary results with low-dose IPLEX. We believe a product that improves fat distribution while also improving insulin sensitivity would be a valuable therapy for this patient population, and the positive effects on insulin sensitivity observed in this study are consistent with what we observed in our previous studies with IPLEX in patients with diabetes. These results support the most important differentiating property of our product in this patient population, which is IPLEX's ability to improve glucose homeostasis. Competitor products such as TH9507 and growth hormone reportedly either do not alter glucose homeostasis or exacerbate it, respectively. When considering that up to 40% of this population has impaired glucose homeostasis, then this property of IPLEX becomes even more valuable," said Dr. Geoffrey Allan, president and Chief Executive Officer of Insmed.
Study Description
The ongoing, open-label, investigator-sponsored Phase II clinical study is designed to evaluate the safety and efficacy of IPLEX in two cohorts of subjects, the first of which received a 0.5 mg/kg/day dose and the second of which will receive 1.0 mg/kg/day dose. The primary endpoints of the study are to determine the safety and tolerability of IPLEX and its effects on visceral fat and insulin sensitivity.
About HARS
An estimated 80,000 HIV patients in the U.S. have HARS, according to published reports. This disorder is marked by abnormal metabolism, including central fat accumulation (visceral adiposity and buffalo hump) with or without fat loss in the limbs. These features have increased markedly with the advent of highly active antiretroviral therapy (HAART) for HIV. Recent studies performed in subjects on HAART suggest nearly 40% of individuals develop the morphologic features characteristic of this syndrome.
About IPLEX
IPLEX was approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency (Primary IGFD). IPLEX (rhIGF-I/rhIGFBP-3) is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug is also being investigated for various other indications with unmet medical needs, including myotonic muscular dystrophy, retinopathy of prematurity and amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease).
About the University of California, San Francisco
The University of California, San Francisco (UCSF), is a leading university that consistently defines health care worldwide by conducting advanced biomedical research and providing leading life science education and complex patient care. For more information, please visit www.ucsf.com.
About Insmed
Insmed is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com.
Forward-Looking Statements
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding planned clinical study design, our regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the company may lack financial resources to complete development of product candidates, the FDA may interpret the results of our studies differently than we have, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and Insmed disclaims any intention or responsibility for updating predictions or financial guidance contained in this release.
Contact:
Investor Relations International
Haris Tajyar, 818-382-9702
[email protected]--------------------------------------------------------------------------------
Source: Insmed Inc.
This Analysis was requested sometime ago in the «Analysis on Demand (http://www.3stocksonfire.org/trading/index.php?topic=10288.0)» thread, which is available only for 3SOF Premium Members (14-Day Free Trial (http://www.3stocksonfire.org/premium_service.php) available).
1. Profile
Insmed Incorporated (INSM), a biopharmaceutical company, engages in the development and commercialization of drugs to treat metabolic diseases, endocrine disorders, and oncology. Its lead product candidate IPLEX, a recombinant protein product candidate, is in Phase II clinical trials for the treatment of myotonic muscular dystrophy, the common form of adult-onset muscular dystrophy. It is also conducting a Phase II clinical study for investigating IPLEX as a treatment for HIV associated adipose redistribution syndrome; a Phase I clinical study investigating IPLEX as a treatment for retinopathy of prematurity, a disease where the small blood vessels in the back of the eye and the retina grow abnormally; and an expanded access program in Italy to provide IPLEX to physicians for patients with amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and the spinal cord. In addition, Insmed is developing INSM-18, a small molecule tyrosine kinase inhibitor that is under Phase I/II clinical trials for the treatment of breast, lung, pancreatic, and prostate tumors; and rhIGFBP-3, a Phase I clinical product candidate for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company has license and collaborative agreements with Fujisawa Pharmaceutical Co., Ltd. to use IGF-I therapy for the treatment of extreme or severe insulin resistant diabetes; and a license to Pharmacia AB's portfolio of regulatory filings pertaining to rhIGF. Insmed was founded in 1999 and is headquartered in Richmond, Virginia.
2. Stock Price History
(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=40567;image)
Before I begin let me start by saying that I dislike biotechnology stocks in general, and the reason for that is simple, I dislike them because most of them keep diluting shareholder's value. This happens because most biotechnolohy companies don't sell anything and have huge losses, so to survive they need a continuous flow of capital. They get this capital by issuing and selling new shares to investors. Every time a new share is printed existing shareholders see the value of their shares being diminished as they represent less of the company.
On this issue INSM looks like the champion of dilution, with the share count rising 122 fold since 1999. The company printed 21 million new shares just in the first half of 2007.
A second issue, as I look to INSM's profile, I see it has changed. When I first met this company and was still an ignorant on fundamental analysis (I guess that one year from now I'll consider I was an ignorant now), the company was developing IPLEX to cure children whom had a rare disease which made them abnormally small. I see IPLEX is being studied for other uses now.
I don't know enough to know the potential market for these other uses of the drug, or how long they are from being marketed. I just know that whatever rise the stock may have, it will be used to sell some more shares. This has been the history of this company and I don't see any change in the near or medium term future.
This isn't to say it is impossible for INSM to double or triple if there's some of those "bombastic" news releases which characterize biotech stocks. But will it be sustainable? I doubt it.
Anyway, I see sctrben made his analysis on the stock and likes it, so I just wish I'm wrong or incomplete, good luck :)
This Analysis was requested sometime ago in the «Analysis on Demand (http://www.3stocksonfire.org/trading/index.php?topic=10288.0)» thread, which is available only for 3SOF Premium Members (14-Day Free Trial (http://www.3stocksonfire.org/premium_service.php) available).
Somehow you forgot quite some items though.
INSM has an expanded acces program for ALS patients in italy.
Iplex used for ALS, reimbursement near 140.000 euros per patient.
Patient count earlier this summer 30. Few month legal hurdle for patients to get it reimbursed fully.
Also there are opt-in agreements with genentech and trca upon phase III enabling data.
Which means once phase IIb trials are complete they have 90 days to opt-in.
Agreement is 50% of all PAST and 50% of all future cost in return for sharing the profits.
Now iplex has cost quite a bit to research, 50% of past cost would amount to quite a sum, even more so if you consider current cashburn of ~1,5million dollar per month and that does not include increases in the ALS program.
They also have the capacity to produce up tp 3-4 biologics in their own fda approved itp facility where they produce the very complex igfbp3 compound as well.
Also recent investment report on INSM
http://www.xs4all.nl/~surg3on/INSM/Biotech.evaluation-Oct.07-INSM.NAS.pdf
If you would be so kind to comment there
Seeing curretn market cap this IS one of he gold nuggets out there with a 2-13 month timeframe for considerable gains. and a 1-4 year timeframe for full appreciation!
Investor presentation from July (with ceut) for rough overview as well
http://www.xs4all.nl/~surg3on/INSM/CEUT.presentation.july.12th.2007/
Update on ALS reimbursement
450 euros = Italian ALS reimbursement per patient per day :
thats 164.200 euros per year equals to 234.000$ us dollars
http://www.sangiovannirotondonet.it/index.php?option=com_content&task=view&id=970&Itemid...
breakout on increased volume and no news yet
Strange but nice ! news around the corner Read_This_? :) ::)
Quote from: IdFix on October 05, 2007, 03:49:25 PM
Strange but nice ! news around the corner Read_This_? :) ::)
well, catalysts are known:
http://www.xs4all.nl/~surg3on/INSM/CEUT.presentation.july.12th.2007/20.png
do expect them to bring in a partner for fob
volume spike last friday
white candle
closed just below 200 dma
Nice call on this one Read_Thi$ :P
MA2OO broken ...1$ hit today !!!
Great slide
http://www.xs4all.nl/~surg3on/INSM/INSM.biogenerics.Update.oct.2007/20.jpg
http://www.3stocksonfire.org/trading/index.php?topic=6858.315
Biogenerics update !!!
INSM biogenerics update
i still will see them sign a partner there this year
fairly easy for those skilled in the art and they see the benefits from being a US based production site
presentation yesterday
http://www.xs4all.nl/~surg3on/INSM/INSM.biogenerics.Update.oct.2007/20.jpg
direct presentation link:
http://webcastingplayer.corporate-ir.net/player/PlayerHost.aspx?EventId=1657597&StreamId=984937&...
stored windows audio file and slides
http://www.xs4all.nl/~surg3on/INSM/INSM.biogenerics.Update.oct.2007/
Quote from: read_this_n0w on October 11, 2007, 01:18:29 PM
Great slide
http://www.xs4all.nl/~surg3on/INSM/INSM.biogenerics.Update.oct.2007/20.jpg
http://www.3stocksonfire.org/trading/index.php?topic=6858.315
That post could have been ran on the INSM thread in the first place.
Do not start new threads...Thank You !
This post has bee merged to the INSM thread.
Big in the after hours.......
INSMED INC(NasdaqCM: INSM)
After Hours: 0.90 +0.36 (+66.36%)6:07PM ET
Recent news.......
Press Release Source: Insmed Inc.; Premacure AB
Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
Tuesday September 23, 8:00 am ET
- Premacure to Initiate Phase II Trial for IPLEX(TM) in Retinopathy of Prematurity -
RICHMOND, Va. and UPPSALA, Sweden, Sept. 23 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM - News), a developer of follow-on biologics (FOBs) and biopharmaceuticals, and Premacure AB, a biopharmaceutical company dedicated to the development of diagnosis and prevention of complications in neonates due to premature birth, today noted the presentation of clinical study results demonstrating that Insmed's IPLEX(TM) product, a complex of recombinant human insulin-like growth factor (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3), increased serum IGF-I levels into the normal range in significantly premature infants. Premacure is developing IPLEX(TM) as a potential treatment for Retinopathy of Prematurity (ROP) via a Material Transfer Agreement with Insmed.
These most recent study results were reported today at the European Society for Pediatric Endocrinology 47th annual meeting, Istanbul, Turkey, by Investigators from the Harvard Medical School, Boston MA, and the University of Gothenburg, The Karolinska Institute, Stockholm, Lund University, Sweden, in a poster entitled "Pharmacokinetic study of recombinant human (rh) insulin-like growth factor/rh IGFBP-3 complex administered to very low birth weight infants."
"The possibility of preventing ROP and other complications of prematurity by replicating the in utero environment after infants are born prematurely and lose the factors normally provided by the maternal environment is very exciting," said Lois Smith, Professor of Ophthalmology, Harvard Medical School, Children's Hospital Boston. "This work showing that it is now possible to raise the serum level of IGF-1 and IGFBP-3 to normal in utero levels in these fragile infants with IGF-1 / IGFBP-3 deficiency is a critical step in the development of interventions that prevent ROP. Since we have shown that low IGF-1 is associated with ROP, this offers the first possible intervention to prevent this blinding disease."
"Our research focuses on promoting neural, vascular and metabolic development in premature infants," said Ann Hellstrom, Professor in Pediatric Ophthalmology, Sahlgrenska Academy, Gothenburg, Sweden. "While in this study we are attempting to identify the benefits of IGF-I for ROP, our findings are also likely to be applicable to many aspects of complications of premature birth and could provide benefits for a lifespan."
"This is a crucial step in the clinical development of a preventative treatment against lifelong severe visual impairment or blindness in infants born preterm," said Jan Borg, CEO of Premacure. "Based in part on these results, we intend to initiate a phase II multicenter trial in the ROP indication during the fourth quarter."
"The ability of IPLEX(TM) to raise serum levels of two key proteins involved in the pathogenesis of ROP safely may offer a more effective preventive option in at-risk infants than the highly invasive and destructive treatment options of laser therapy or cryotherapy that are currently utilized to stem disease progression only," said Geoffrey Allan, President and CEO of Insmed. "We are pleased that researchers at such distinguished universities continue to see promise in IPLEX(TM) in ROP and intend to continue evaluating the drug in this indication. Moreover, these results serve as further evidence of the effectiveness of IPLEX(TM) in potentially treating some of the most under-served therapeutic populations, including Myotonic Muscular Dystrophy and Amyotrophic Lateral Sclerosis."
Clinical Study Results
Low levels of IGF-I are known to contribute to the pathogenesis of ROP. The objectives of this open label, investigator-sponsored clinical study were to determine whether intravenous administration of rhIGFI/rhIGFBP-3 (IPLEX(TM)) could increase serum levels of these proteins in at-risk infants to levels seen in normal infants, and to evaluate the drug's safety and tolerability. Due to consistency in response, the study was finalized after five infants. The gestational age in these infants ranged from 26 weeks + 0 days to 29 weeks + 1 day (birth weight 810-1,310 g). Treatment with IPLEX(TM) took place on the infant's chronological age day 3 and the investigators reported that the protein complex effectively raised serum IGF-I levels into the physiological range and that the drug's administration was well tolerated, with no acute adverse events.
About IPLEX(TM)
IPLEX(TM) is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug, approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency, is currently being investigated in MMD and ALS.
About ROP
ROP is a disease of the eye that affects prematurely born babies. It is thought to be caused by disorganised growth of retinal blood vessels which may result in scarring and retinal detachment. ROP can be mild and may resolve spontaneously, but may lead to blindness in serious cases. It is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness. As such, all preterm babies are at risk for ROP, and very low birth weight is an additional risk factor.
About Premacure AB
Premacure AB, based in Uppsala, Sweden is a biopharmaceutical company dedicated to the development of diagnosis and prevention of complications in neonates due to premature birth. The first of several indications to be developed is Retinopathy of Prematurity (ROP) a retinal disease being one of the major causes of blindness in infants throughout the world. Contact: Jan Borg, CEO,
[email protected].
About Insmed
Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, the FDA may not establish specific guidelines for a pathway for the approval of FOB products, FOB products may not be accepted by consumers, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
--------------------------------------------------------------------------------
Source: Insmed Inc.; Premacure AB
I like the chart!!
Price goes up as volume goes up 4 days in a row. Time for a retracement.
Placed an buy order @ 1.08 (I might revise that up a few cents)